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ABSTRACT
Genomic imprinting is a mechanism that targets epigenetic modifications to regulate gene
transcription to express a gene from only one of its two parental alleles. Imprinted genes are
typically clustered together and are involved in developmental regulation of the fetus. The
paternally expressed gene 3 (Peg3) domain represents one such imprinted gene cluster involved
in fetal growth regulation and maternal caring behavior. The transcription and imprinting control
of the Peg3 domain requires the transcription factor Yin-Yang 1 (YY1), a protein that plays
important roles throughout development.
The first part of this work explores evidence for the hypothesis that half a dosage of YY1
may be involved in controlling the transcription and imprinting of Peg3 in vivo. The results
reveal that Yy1 most likely functions as a transcriptional repressor in this domain. The results
also provide new evidence for bi-allelic expression of Peg3 in the mouse brain. Altogether, this
indicates that the maternal allele of Peg3 is expressed and functional in specific areas of the
brain, including the choroid plexus, paraventricular nucleus (PVN), and the supraoptic nucleus
(SON).
The observed bi-allelic expression pattern indicates either de-repression of the maternal
allele of the known promoter or the presence of alternative promoters for the Peg3 locus.
Therefore, the second part of this work demonstrates that several alternative promoters exist for
Peg3. The results reveal that these alternative promoters display allele-, tissue-, and
developmental stage-specific expression patterns. This suggests that the activity of these
alternative promoters have been functionally selected features for the Peg3 imprinted domain
during mammalian evolution. The third part of this work develops a novel methodology that
detects alternative promoters for Peg3 by incorporating both 5’ rapid amplification of cDNA
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ends (5’RACE) and next-generation sequencing (NGS) techniques. The results indicate that this
NGS-based 5’RACE protocol is a sensitive and reliable method for detecting low-abundant
transcripts and promoters.
Overall, the research presented in this dissertation advances our understanding of how the
YY1 transcription factor is involved in controlling the Peg3 imprinted domain and how
alternative promoters may contribute to the allele-, tissue- and developmental stage-specific,
Peg3 expression patterns observed in the mouse.
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CHAPTER 1
INTRODUCTION
1.1 Transcriptional regulation
The central dogma of molecular biology governs the mechanisms underlying each living
organism, from prokaryotes to eukaryotes [1, 2]. This includes the transcription of DNA
molecules to RNA and translation of the RNA molecules to protein. In eukaryotes,
transcriptional regulation is achieved through interactions between the regulatory elements that
recruit proper transcription factors required for RNA polymerase II assembly and its activity.
This depends on the accessibility of the RNA polymerase II to DNA, in order to generate
messenger RNA molecules (mRNA) [3].
In eukaryotic gene transcription, a promoter sequence is required for RNA polymerase to
initiate transcription. These regions recruit transcription factors, activators, repressors and RNA
polymerase II to enable proper interactions to enable transcription. However, eukaryotic gene
transcription is a complex process, which utilizes long-range DNA interactions between
enhancers and promoters to initiate transcription. Gene transcription in mammals is a tightly
regulated process that incorporates multiple cell-type, tissue-, and developmental stage-specific
gene expression patterns with the help of alternative promoters, splicing variations and long noncoding RNA (lncRNA) [3-5]. The current study intends to gain a better understanding of this
process.
Chromatin structures affecting epigenetic regulation can be observed through active and
repressive

histone

modifications

that

result

from

histone

methylation,

acetylation,

phosphorylation and ubiquitination [3]. For instance, H3 lysine 4 trimethylation (H3K4me3), and
H3 lysine 9 acetylation (H3K9ac) encode histone marks responsible for actively transcribed
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promoter regions. On the other hand, H3 lysine 9 trimethylation (H3K9me3), and H3 lysine 27
trimethylation (H3K27me3) marks are associated with constitutively and facultatively repressed
genes, respectively [6, 7]. It is still unknown whether these modifications are the cause or an
effect of the associated chromosomal arrangements.
Another epigenetic modification that controls gene expression is DNA methylation,
where the covalent addition of a methyl group to a CG dinucleotide (CpG) occurs via de novo
methyltransferases [8]. In many cases, this can either inhibit or facilitate the binding of required
transcription factors to the promoter region of a given gene to regulate transcription. Moreover,
DNA methylation is tightly linked to histone modifications in forming compact, heterochomatic
regions. Thus, it is involved in a multitude of transcriptional processes such as genomic
imprinting, X-chromosome inactivation, cancer, aging, and repression of repeat elements [8, 9].

1.2 Genomic imprinting
In sexually reproducing organisms, offspring typically inherit an equal representation of
genetic material from both parents. Most genes are equally expressed from two copies, or alleles,
with one allele derived from each parent. However, a subset of these autosomal genes shows
expression from only one of these alleles due to a process termed genomic imprinting [9]. This
process exists in higher order organisms such as plants, fungi, and animals; and in mammals it is
found within two subclasses [9-11]. These include the marsupials and placental mammals, which
implement genomic imprinting to regulate their complex reproductive systems to control
intricate interactions between the mother and the developing fetus [12-14]. According to the
parental conflict hypothesis, this embryonic regulation is a result of paternally expressed genes
promoting growth and maternally expressed genes suppressing the growth of the developing
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embryo [15]. Mammalian genomic imprinting plays critical roles in regulating fetal growth,
development, and neurological processes such as maternal behavior [9, 12]. As a consequence,
dysfunctional genomic imprinting is implicated in several human diseases, including PraderWill, Angelman, Beckwith-Wiedemann, Silver-Russel syndromes, and autism spectrum
disorders [16, 17].
The existence of genomic imprinting in mammals was first demonstrated over three
decades ago by nuclear transfer technology when it failed to generate viable androgenetic
embryos (having two paternal genomes) or gynogenetic embryos (having two maternal genomes)
in mice [18, 19]. A typical imprinted domain contains a 3-12 imprinted genes spanning roughly
100-1700kb of genomic regions, including at least one lncRNA [9]. They are sensitive to
environmental cues, which in turn result in altered cis-acting regulatory mechanisms using
epigenetic factors such as DNA methylation, histone modifications, and non-coding RNA. Based
on known imprinted gene clusters, a typical imprinted domain is controlled by an imprinting
control region (ICR). For instance, paternally expressed genes acquire their maternally imprinted
DMR in gametes during oogenesis, while the maternally expressed genes obtain their paternally
imprinted DMR in gametes during spermatogenesis [20]. These DNA methylation imprints are
effectively erased by demethylation of CpGs during the primordial germ cell stage (gamete
production) of development [21].
This phenomenon was confirmed by the identification of two mouse gene clusters
including three imprinted genes, Insulin-like growth factor 2 receptor (Igf2r), Igf2, and H19,
which showed parental-specific expression patterns [22-24]. The imprinting control of these gene
clusters is explained by two current models (Figure 1.1). One is the lncRNA-mediated silencing
model, and the other is the insulator model. The Igf2r locus is regulated by the lncRNA-mediated

3

silencing model, which contains three maternally expressed genes (Slc22a2, Slc22a3, and Igf2r),
and a paternally expressed Airn lncRNA (anti-sense to Igf2r) that serves as the ICR for this
region [25].

Figure 1.1. Mechanisms of genomic imprinting. The black arrows indicate the direction of
transcription. The open and closed circles represent unmethylated and methylated DNA,
respectively. (A) The lncRNA model illustrated by the Igf2r cluster. The methylated ICR on the
maternal allele silences the Airn non-coding RNA expression, allowing RNA polymerase II to
transcribe maternally expressed Igf2r, Slc22a2, and Slc22a3. When unmethylated, the ICR
enables the Airn non-coding RNA to silence the maternally expressed genes. (B) The Insulator
model is illustrated by the Igf2 cluster. The enhancer (E) transcribes the H19 non-coding RNA
when the CTCF transcription factor occupies the unmethylated ICR on the maternal allele. The
paternal allele is free of CTCF, thereby allowing E to interact with Ins and Igf2.
The methylated ICR of the maternal chromosome directly silences the Airn promoter, enabling
the transcription of Slc22a2, Slc22a3, and Igf2r by recruiting RNA polymerase II [26]. On the
contrary, the unmethylated ICR of the paternal chromosome activates the Airn lncRNA
promoter, silencing Slc22a2, Slc22a3, and Igf2r through cis regulatory mechanisms. In the
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endoderm, the Igf2 locus is regulated by the insulator model, which contains maternally
expressed lncRNA H19, paternally expressed genes Igf2 and Ins2, and a gametic DMR serving
as an ICR [27]. The unmethylated ICR of the maternal chromosome interacts with a transcription
factor, CTCF, which acts as an insulator to prevent the enhancer interaction with the Igf2 and Ins
genes. This enables the transcription of the H19 lncRNA. On the other hand, the methylated ICR
of the paternal chromosome activates the Igf2 and Ins genes, inactivating H19 transcription due
to the lack of CTCF binding interactions [28, 29]. Tight regulation of these gene clusters is
required as they play essential roles in growth and development before birth [9].

1.3 Peg3 imprinted domain
Along with fetal growth and development, imprinted domains in the mouse also play
critical roles in maternal caring behavior. This is seen from a gene cluster found in the paternally
expressed gene 3 (Peg3) imprinted domain in mouse chromosome 7. Peg3 was first discovered
over two decades ago during the study of hybrid cDNA libraries from parthenogenetic embryos
[30]. Shortly afterwards, Peg3 was identified for its critical roles during the development and
differentiation of the central nervous system and skeletal muscles [31]. The human homolog of
Peg3 was then discovered during gene mapping and mRNA expression analyses spanning the
human chromosome 19q13.4 [32]. Peg3 encodes a Krüppel-type, 2 cysteine 2 histidine (C2H2)
zinc finger protein that functions as a transcription factor [30-32]. In many cases, an increase in
DNA methylation, or hypermethylation, leads to a reduction in gene transcription. Peg3 is
hypermethylated in breast and ovarian cancer patients, implicating that it may function as a
tumor suppressor [33, 34]. In addition, Peg3 also plays important roles in regulating fetal growth
rates and maternal caring behavior in mice [35-37]. The Peg3 gene resides within a cluster of
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imprinted genes within a 500-kb domain, and is evolutionarily well conserved among all
placental mammals [38]. Although Peg3 has been studied extensively for years, many of the
underlying mechanisms of its gene and protein regulation are still unclear.
The imprinted domain of Peg3 includes four paternally expressed genes Peg3, Ubiquitinspecific hydrolase 29 (Usp29), Antisense Peg3 (Apeg3), Zinc finger protein 264 (Zfp264), and
three maternally expressed genes Zinc finger gene, imprinted 1, 2, and 3 (Zim1, Zim2, and Zim3),
as shown in Figure 1.2 [39-43]. These genes are conserved among placental mammals, with the
exception of Zim1, which is found only in mammals with large litter sizes [38]. The Peg3
domain was evolutionarily dynamic in nature, as there are subtle changes between the mouse and
human domains that led to significant changes in functionality. For instance, the full-length
mouse Usp29 homolog in human, is separated into two genes, MER1 repeat containing
imprinted transcript 1 (MIMT1) lnc-RNA, and protein coding USP29 in humans [44]. Moreover,
Peg3 and Zim2 genes are fused in humans, sharing the same promoter and multiple alternative
splicing variants [45]. All of these imprinted genes are clustered unevenly in the ends of the 500kb domain, leaving a 250-kb conserved region that lacks any open reading frames (ORFs) in the
center [38]. This region, however, contains multiple evolutionarily conserved regions (ECRs)
that are most likely involved in controlling the Peg3 domain via cis-regulatory mechanisms [46].
For example, a series of chromosome conformation capture, and in vitro promoter assays
indicated that ECR18 interacts with the Peg3 promoter, and is also associated with histone
modifiers that correlate with enhancer activity. These include H3 lysine 4 mono-methylation
(H3K4me1), and H3 lysine 27 acetylation (H3K27ac). The enhancer activity of this particular
ECR has also been reported to act in a tissue specific manner [46]. These ECRs require further
investigation for their functional significance, as some of the genomic architectures of enhancers
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are shared with promoters as well [47].

Figure 1.2. Genomic structure of the Peg3 imprinted domain. The pink and blue boxes denote
maternally and paternally expressed genes, respectively. The grey boxes represent the
differentially methylated regions (DMR) and the imprinting control region (ICR) of the domain.
The two parallel lines indicate that the region is shortened for presentation. The 250-kb region
within the mouse Usp29 is conserved between mammals. The DNA lengths are not drawn to
scale. The closed and open circles represent methylated and unmethylated DNA, respectively.
(A) Genomic structure of the mouse Peg3 locus found in chromosome 7. (B) Genomic structure
of the human PEG3 locus found in chromosome 19q13.4. From mouse to human, Usp29
diverged into MIMT1 and USP29, while the Zim2 fused to PEG3. The maternally expressed
ZIM2as is an additional non-coding RNA that is added to the human PEG3 locus through
evolution.
The seven imprinted genes of the Peg3 imprinted domain are transcribed using five
promoters, two of which are bidirectional promoters shared by Peg3/Usp29 and Zim3/Zfp264 in
mice [38]. DNA methylation analyses have identified Peg3/Usp29, Zim2, and Zim3 promoter
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regions as DMRs of this domain. However, Peg3-DMR acquires its gametic DNA methylation
during oogenesis, and functions as the ICR for this domain [48-51]. This DMR spans the 4.0-kb
genomic region that harbors the bidirectional Peg3/Usp29 promoter and their respective first
exons (which occupies around 1.5-kb of the Peg3-DMR), as well as an unusual tandem array of
repeat sequences that spans the first intron of Peg3 (which occupies the remaining 2.5-kb of
Peg3-DMR) [52]. This array contains a well-conserved GGCGCCATCTT motif, which serves as
a DNA binding site for the transcription factor Ying-Yang 1 (YY1), further discussed in section
1.4. This motif is repeated 7 times in the mouse Peg3-DMR and 10 times in the human Peg3DMR (Figure 1.3) [53, 54]. Researchers extensively use gene deletion based models to study the
effect of certain genes or proteins by inactivating or disrupting it with the use of genetic and
molecular mechanisms. A 2.5-kb deletion of this ICR region leads to a down-regulation of the
Peg3 expression, biallelic expression of Zim2, and a switch in the dominant allele of Zfp264
from paternal to maternal allele expression [50]. This switch hints to an unknown function for
the maternal allele of the Peg3-DMR, thus indicating the significance of the ICR in imprinting
and transcription of the Peg3 domain [50].
Similar to many of the imprinted genes, Peg3 and Zim1 are highly expressed in the
placenta, developing embryos and the hypothalamus region of the brain involved in controlling
many of the maternal caring behaviors [12, 30-32, 55]. Such is the case for many of the
remaining imprinted genes within the domain, where Zim2 and APeg3 are also expressed in the
hypothalamus region [35, 56]. Recent gene deletion experiments involved in the Peg3 locus have
indicated that offspring produced from the paternal transmission of the mutation are more
susceptible to perinatal lethality. This is due to their difficulties with milk intake or suckling,
compared to their wildtype littermates. Once the affected survive to adulthood, these mutant
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mice still maintain a stunted growth phenotype compared to their littermates. However, these
differences were not as pronounced in the maternal transmission of the mutation [35, 36]. Adult
mice lacking the PEG3 protein have also indicated similar phenotypes where the paternally
transmitted mutant females lack proper nest building capabilities and problems with milk
letdown [37]. The in vivo functional studies on Peg3 to date are based on either a paternal or a
maternal deletion of the mutant allele, assuming that the Peg3 maternal allele is methylated, and
is thus functionally silent. However, the maternal allele of Peg3 may have previously undetected
low levels of expression based on studies described in the following chapters.

Figure 1.3. YY1 binding sites in the mouse Peg3 locus. The maternal and paternal genomic
structure of Peg3 represents the transcriptional directions for each gene. The closed and open
circles indicate the methylated and unmethylated DNA in found in the ICR, respectively. There
are seven YY1 binding sites spanning the ICR of the Peg3 locus. This occurs within the first
intron of Peg3, and is shown by the orange triangles that interact with the YY1 transcription
factor.
9

1.4 YY1 transcription factor
The Peg3 imprinted domain includes a conserved repeat sequence that corresponds to
several Yin-Yang 1 (YY1) binding sites found near the first intron of Peg3. Thus, the
transcription factor YY1 may be involved in controlling the transcription and imprinting status of
the Peg3 imprinted domain. YY1 is a multifunctional protein that possesses the dynamic ability
of both transcriptional activation and repression [57]. In addition, YY1 can regulate its own
transcription by binding to its conserved internal DNA-binding sites found in the first intron of
the Yy1 gene during transcription [58]. YY1 is an evolutionarily conserved C2H2 GLI-Krüppeltype zinc finger protein, ubiquitously expressed in vertebrates. YY1 is also an ancient protein
with homologs in invertebrates, including Pleiohomeotic (PHO) protein in insects, and PHO-like
(PHOL) factor in Drosophila [59-61]. The PHO protein is an important component of the
polycomb-group (PcG), which is responsible for silencing of developmental genes through
chromatin modulation [61]. On the other hand, Yin-Yang 2 (YY2) and reduced expression 1
(REX1) proteins show sequence homology to YY1. YY2 is similar in function to YY1, while
REX1 has structural similarities as well as a few functional similarities to YY1 at its four zinc
finger domains. Although YY2 and REX1 have undergone similar retro-transposition events,
they have co-evolved to have unique functions in eutherian mammals when compared to YY1
[62, 63].
In 1991, YY1 was originally discovered as a transcriptional repressor that binds the
promoter region (P5) of an adeno-associated virus in the absence of an adenovirus inducible
element (E1A) [64]. Proteins NF-E1 (YY1), and NF-δ (the mouse ortholog of YY1) were found
around the same time period due to their regulatory roles in immunoglobin promoters and
enhancers [57, 65]. Thus, three independent groups simultaneously discovered YY1 and
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described similar functionality [57, 64, 65]. YY1 is also involved in the tight regulation of
protein-protein interactions in cancer progression. For instance, YY1 plays an important role in
controlling the p53 tumor suppressor through multiple pathways, including its interactions with
the p53 antagonist, mouse double minute 2 protein (MDM2) [66]. YY1 involvement with histone
acetyltransferases (P300, CBP) and histone deacetylases (HDAC1, HDAC2, HDAC3)
demonstrates its connection to histone modification as well [66, 67]. Additionally, YY1 shows
sensitivity to developmental and environmental indicators as it interacts with proteins involved
with epigenetic modifiers such as polycomb repressive complex 1 (PRC1), KRAB A boxassociated protein 1 (KAP1), and histone-lysine N-methyltransferase SETDB1 [38, 68].
Moreover, it has been shown that YY1 may also bind to other genes using specific binding sites
in a DNA methylation-sensitive manner [52]. Thus, YY1 may be involved in controlling the
genes involved with genomic imprinting.
Some YY1 binding sites have been shown to cluster near ICR regions in mammals [69,
70]. This includes imprinted loci such as Peg3, Xist, Gnas, and Snrpn [69, 71]. For instance,
reducing levels of YY1 protein by the use of in vitro and in vivo RNA interference (RNAi)
mediated YY1 knockdown methods lead to up-regulation of Peg3 expression and altered DNA
methylation levels throughout the Peg3 domain, indicating that it may be a major trans factor
that regulates transcription and imprinting [54, 71, 72]. YY1 likely plays a role in the de novo
DNA methylation of the Peg3-DMR during oogenesis, as in vivo YY1 knockdown in oocytes
and blastocysts indicated a loss of DNA methylation in this domain [54]. However, it is still
unknown how YY1 regulates the DNA methylation of these ICR regions in these imprinted
domains. Therefore, YY1 roles in these imprinted domains require further characterization, using
additional in vivo knockout models with lower YY1 protein levels to confirm the data obtained
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from the RNAi-mediated knockdown experiments. Targeted disruption of the Yy1 gene in mice
shows that homozygous mutants of Yy1 (Yy1-/-) embryos do not survive beyond early
embryogenesis during implantation, which suggests that YY1 has a strong connection to cell
proliferation and differentiation [73]. The role of YY1 in the Peg3 imprinted domain may be
further examined by utilizing a heterozygous mouse model with a mutation at the Yy1 locus.

1.5 Alternative promoters and detection
In eukaryotic organisms, gene transcription is a complex process that requires careful
assembly of multiple trans-acting factors as well as cis-acting DNA elements such as promoters
and enhancers. For instance, the Peg3 imprinted domain includes trans-acting factors such as
YY1, and cis-acting factors such as the ICR, the ECRs, and the five promoter regions. The cisregulatory regions spanning the 200-kb evolutionarily conserved region in the Peg3 domain are
hypothesized to be involved in tissue-, allele-, and developmental stage-specific expression
patterns [38, 46]. In fact, these differences in expression may be responsible for the tight
regulatory functions of its domain.
According to multiple high throughput and next-generation sequencing (NGS) methods,
the current human genome consists of over 25,000 genes that are responsible for the production
of over 100,000 protein-coding and non-coding transcripts [74]. This suggests that majority of
the known genes encode for more than one transcript due to variations in transcription initiation,
splicing, and polyadenylation. The initial control of gene expression is regulated by
transcriptional initiation through the use of promoters [75]. A typical promoter region consists of
DNA sequences that enable the recruitment and proper assembly of transcription factors and
RNA polymerase II to begin transcription of the respective gene at its first exon. On the other

12

hand, alternative promoters form transcripts that differ in their first exon or the length of the 5’
untranslated region (5’-UTR), utilizing upstream genomic regions instead of the canonical
promoter [74]. This can either generate different ORFs that result in alternative protein isoforms,
or the same ORFs with a different 5’-UTR, which can influence both transcriptional and
translational regulation (Figure 1.4). Many of the transcripts that originate from alternative
promoters also include exon-skipping events, as these are interdependent mechanisms [4].
Further investigation of alternative promoters and splicing variants suggest their involvement in
differential gene expression patterns observed in various mammalian tissues, development
stages, and cell types [4]. This indicates that the misregulation of alternative transcription may
result in various developmental disorders, neuropsychiatric disorders, and cancerous cell growth
[4, 76, 77].
In recent studies, the spatial and temporal regulation of alternative transcription results
from multiple genetic and epigenetic regulatory mechanisms that occur near the promoter
regions. These include histone modifications, changes in DNA methylation, and long-range
interactions between the promoter and distal elements such as enhancers that determine the
accessibility to RNA polymerase II [47, 74]. For instance, strong alternative promoters often
acquire H3K4me3, while developmentally regulated alternative promoters include H3K4me3 as
well as H3K27me3 [78]. Moreover, a combination of H3K4me1/H3K4me2, H3K27ac are
responsible for enhancer-like chromatin signatures that are involved in recruiting the
transcriptional machinery and RNA polymerase II [47, 79]. Thus, it is important to note that the
histone architecture where promoters, alternative promoters, and enhancers are localized, share
similar modifications, suggesting that some enhancers may also promote a very low level of
transcription [47].
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Figure 1.4. Transcriptional regulation using alternative promoters. The blue rectangles and
circles represent exons and protein of a given gene. The green rectangles and pentagons
represent alternative exons and protein isoforms of the same gene. H3K4me3 histone
modification is typically found at the +1 region of the DNA. (A) A typical promoter region
consists of DNA sequences that recruit RNA polymerase II to transcribe mRNA, which is then
spliced and processed before translating into protein. (B) An alternative promoter is usually
found upstream of a typical promoter, generating the same protein isoform as the typical
promoter. (C) An alternative promoter could also generate a different protein isoform based on
its start codon or the ORF.
These alternative transcriptional events are also present in imprinted domains, which are
particularly susceptible to epigenetic changes. For example, the small nuclear ribonucleoprotein
polypeptide N (SNRPN) gene locus is an imprinted domain associated with Prader-Willi
syndrome and Angelman syndrome. The mouse and human SNRPN genomic region span a 500kb domain, a length that dwarfs its 20-kb protein-coding region. The remaining genomic region
14

lacks any ORFs, similar to the 200-kb conserved region found in the Peg3 imprinted domain.
This genomic region harbors multiple alternative promoters for SNRPN and antisense transcript
of ubiquitin protein ligase E3A (UBE3A-ATS), some of which are responsible for setting
germline-specific DNA methylation [80-82]. The gene for guanine nucleotide binding protein
(GNAS) has a complex imprinted domain that includes maternally, paternally, and biallelically
expressed transcripts that allow proper regulation in the signal transduction pathway. Among the
multiple tissue and allele-specific alternative promoters found in the GNAS domain, one is
responsible for establishing DNA methylation for the downstream canonical promoter in oocytes
[83, 84]. Moreover, deep RNA sequencing (RNA-seq) and de novo transcriptome assembly of
stage-specific mouse oocytes have indicated that many imprinted genes including pleiomorphic
adenoma gene-like 1 (Plagl1/Zac1) contain alternative promoters that may be sensitive to DNA
methylation [85]. In addition, the study also suggests that Peg3 may also contain a similar
alternative promoter in the Usp29 region of the domain [85]. Thus, it would be of interest to
investigate the existence of possible alternative promoters for Peg3, as this may uncover new
functions for PEG3 that are tissue-, allele-, and developmental stage-specific. Thus, the prospect
of alternative promoters for Peg3 is discussed in chapter three.
As alternative transcription is involved in critical functional roles during development,
the study of specific transcriptional variants are imperative to its understanding. Currently, RNAseq is the most common method of detection for alternative transcription, since it has the ability
to reveal the number, structure and abundance of a given alternative transcript. However, it is
difficult to predict the strength of alternative promoters and their proper exon structures
including exon-intron junctions using this method [74]. Another method that is able to overcome
these caveats is 5’ rapid amplification of cDNA ends (5’ RACE) [86]. This technique detects
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full-length cDNA from either the 5’ or the 3’ end of a given gene, incorporating a cloning
strategy to identify low-abundance transcripts [86]. In comparison to RNA-seq, this method is
not sensitive enough to quantify a multitude of transcripts. A novel method that merges both
5’RACE and NGS techniques may solve this problem and allow detection of alternative
promoters, and is discussed in the following chapters.

1.6 Statement of research objectives
The process of genomic imprinting has been extensively studied for over three decades,
as imprinted genes play critical roles during embryonic development. There are still ongoing
investigations to understand how these genes acquire their DNA methylation imprint during
gametogenesis. Since few imprinted genes are well studied, many of them have unknown
regulatory mechanisms. Peg3 is one such gene, as many aspects of its gene and protein
regulation is still unclear. As suggested by previous in vitro and in vivo mouse knockdown
experiments, this domain harbors several YY1 binding sites indicating that this transcription
factor is likely involved in regulating Peg3 transcription. The first aim of this work is to
understand how YY1 is involved in controlling the Peg3 domain in a dosage dependent manner
in vivo.
Over the past two decades, Peg3 was thought to be a gene exclusively expressed from the
paternal allele. Thus, many of the in vivo functional studies of Peg3 are based on either a
paternal or a maternal deletion of the mutant allele, assuming that the Peg3 maternal allele is
functionally silent. However, this may not be the case according to the unexpected observations
made while addressing the first aim. Peg3 is bi-allelically expressed in specific areas of the
mouse brain including the choroid plexus, supraoptic nucleus, and the paraventricular nucleus of
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the hypothalamus. In fact, this suggests that the maternal allele of Peg3 is functional and may
harbor an allele-specific alternative promoter for its transcription. The second aim of this work is
to identify such alternative promoters that are responsible for maternal allele expression of Peg3
in the mouse hypothalamus.
Although there are several methods to detect alternative promoters, they are not sensitive
enough to determine transcripts that are of low abundance. For instance, Peg3 is bi-allelically
expressed in a small population of cells in the hypothalamus. This requires a method that is more
efficient than 5’RACE and more sensitive than RNA-seq. Therefore, the third aim of this work is
to introduce a novel method that incorporates an NGS-based 5’RACE method that is specifically
designed to identify low-abundant transcripts initiating from alternative promoters.
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CHAPTER 2
YY1 DOSAGE EFFECT AND BIALLELIC EXPRESSION OF PEG3 1
2.1 Introduction
Peg3 (Paternally Expressed Gene 3) was the first imprinted gene identified from the
evolutionarily conserved 500-kb domain located in proximal mouse chromosome 7/ human
chromosome 19q13.4 [1-3]. Since then, 6 additional imprinted genes have been identified from
this domain, including paternally expressed Usp29, Zfp264, APeg3 and maternally expressed
Zim1, Zim2, Zim3 [4, 5]. As seen in other imprinted domains, the imprinting and transcription of
this imprinted domain is likely regulated through small genomic regions, termed ICRs
(Imprinting Control Regions) [6-8]. One genomic region surrounding the promoters of Peg3 and
Usp29, termed the Peg3-DMR (Differentially Methylated Region), has been hypothesized to be
an ICR for this imprinted domain due to the following features. First, this genomic region has an
unusual tandem array of YY1 binding sites [9-11]. Second, the allele-specific DNA methylation
on the Peg3-DMR is set up during oogenesis and maintained throughout the lifetime of
mammalian species [12-14]. These features are often associated with other ICRs, such as the ICR
of H19/Igf2 [11]. A series of subsequent analyses indeed confirmed ICR roles for the Peg3-DMR
and also the involvement of Yy1 in the transcription control and DNA methylation of the Peg3
domain [15-18]. In particular, the reduced levels of YY1 protein have been shown to up-regulate
the expression levels of the Peg3 domain and also to change the DNA methylation levels of the
Peg3-DMR [15-17]. Thus, it has been hypothesized that Yy1 is a major trans factor regulating the
transcription and imprinting of the Peg3 domain [11].
1
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The protein YY1 is a well-known DNA-binding protein with various functions [19, 20].
YY1 can function as a repressor and an activator for the transcriptional regulation of the
associated genes [19, 20]. YY1 is also known to interact with many protein complexes that are
involved in histone modifications [21, 22]. According to the recent studies, YY1 interacts with
two major epigenetic modifiers, including PRC1 (Polycomb Repressive Complex 1) and KAP1
(KRAB A box-Associated Protein 1)/SETDB1 (histone-lysine N-methyltransferase SETDB1)
[23, 24], which may provide clues regarding potential roles for YY1 in genomic imprinting. In
the case of PRC1, YY1 interacts with PRC1 through YAF2, which might provide a mechanism
for permanent and stable repression for the imprinted genes [23]. On the other hand, the
interaction between YY1 and KAP1 has been shown to be very specific in ES cells [24]. This
cell-type specific interaction might explain the prevalence of YY1 binding sites within the
sequences of all the retrotransposons and endogenous retroviruses as well as potential
mechanisms for the repression of these DNA elements during early embryogenesis [25, 26]. This
protein complex, YY1/KAP1/SETDB1, is particularly relevant to genomic imprinting since
DNA methylation on several ICRs with YY1 binding sites all occur during early embryogenesis
and gametogenesis [11, 17]. Nevertheless, it is currently unknown how YY1 is involved in
establishing DNA methylation on ICRs and other retrotransposons in mammalian genomes.
In the current study, therefore, we sought to characterize the in vivo roles of Yy1 in the
Peg3 domain using various breeding schemes with a set of newly established mutant alleles of
Peg3. According to the results, Yy1 indeed functions as a repressor for the Peg3 domain. During
the course of this study, we have also discovered that Peg3 is expressed bi-allelically in a small
subset of cells in mouse brain.
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2.2 Materials and Methods
Generating the mutant strains for Yy1 and Peg3
The current study used the following 7 mouse strains. The strain carrying a floxed allele
for Yy1 was obtained from the Jackson Lab (Stock No. 014649, B6.129S4-Yy1tm2Yshi/J; [27]). The
strain for the CoKO allele of Peg3 was made using a targeted ES cell from the EUCOMM
(European Conditional Mouse Mutagenesis program), and this strain has been maintained in the
lab [28]. These two strains were crossed with the Zp3-Cre line from the Jackson Lab (Stock No.
003651, C57BL/6-Tg (Zp3-cre) 93Knw/J) and the Rosa26-FLP line from Jackson Lab (Stock
No. 009086, B6.129S4-Gt (ROSA)26Sortm1(FLP1)Dym/RainJ). The mutagenesis through these
breeding derived the Yy1 mutant strain, and also the FlipKO and DelKO strains for the Peg3
locus. The following primer sets were used for genotyping of these strains: the deletion of exon 1
for Yy1, YY1-CoKO-F (5’-ACCTGGTCTATCGAAAGGAAGCAC-3’) and YY1-genotype-R
(5’-TCATCCAAAGTTCGAAACCTGCTTTCC-3’); the presence of the expression cassette for
the CoKO allele, Peg3-5arm (5’-CCCTCAGCAGAGCTGTTTCCTGCC-3’) and LAR3 (5’CAACGGGTTCTTCTGTTAGTCC-3); the deletion and detection of the expression cassette for
FlipKO and DelKO, respectively, Peg3-5arm (5’-CCCTCAGCAGAGCTGTTTCCTGCC-3’)
and LoxR (5’-TGAACTGATGGCGAGCTCAGACC-3’); the presence of Zp3-Cre, Zp3-cre-F
(5’-TAGGAATCACGTGGAGTGTCT-3’)

and

oIMR1085

(5’-

GTGAAACAGCATTGCTGTCACTT-3’); the presence of Rosa26-FLP, oIMR0853 (5’GCGAAGAGTTTGTCCTCAACC-3’) and oIMR0852 (5’-AAAGTCGCTCTGAGTTGTTAT3’). DNA was isolated from ear or tail snipes through incubating the tissues at 65°C with the tail
lysis buffer (50 mM Tris-Cl at pH 8.0, 100 mM EDTA at pH 8.0, 250 mM NaCl, 1% SDS, along
with 20 µg/mL Proteinase K). PCR premix kit (Intron Biotech) was used for genotyping at the
26

following conditions (step 1, 95°C-30 sec; step 2, 95°C-30 sec, 60°C-30 sec, 72°C-60 sec for 33
cycles; step 3, 72°C-7 min). The information regarding individual primer sequences is also
available (Table 2.1).
Table 2.1. Primer sets used for genotyping experiments.

Breeding experiments
The current study used the following three breeding schemes: Breeding I, female
heterozygotes for Yy1 ✕ male heterozygotes for CoKO of Peg3; Breeding II, female
heterozygotes for CoKO ✕ male heterozygotes for Yy1; Breeding III, female heterozygotes for
Yy1 ✕ male heterozygotes for DelKO (Figure 2.1). The health status of the pups from these
breeding was monitored through measuring their birth weight (Figure 2.2 C). The gender of these
pups was also determined through PCR with the following primer set: mSry-F (5’GTCCCGTGGTGAGAGGCACAAG-3’) and mSry-R (5’-GCAGCTCTACTCCAGTCTTGCC3’). All animals were kept in a temperature-controlled environment at 22°C, with 4-5 mice per
cage over a 12-hour period of light/dark cycles. Litter size, genotype, birth weight and gender
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were all recorded for each mating pair, which were later used to generate a graphical
representation of the gender and genotype distribution for each cross (Figure 2.2 A, B).

Figure 2.1. Breeding schemes used to characterize Yy1 roles in the Peg3 imprinted domain. This
study used three breeding schemes: Breeding I, female heterozygotes for Yy1 X male
heterozygotes for CoKO allele of Peg3; Breeding II, female heterozygote for CoKO X male
heterozygotes for Yy1; and Breeding III, female heterozygotes for Yy1 X male heterozygotes for
DelKO allele of Peg3. All of the Peg3 heterozygotes used for these breeding schemes had
inherited the mutant alleles maternally, CoKO (-m/+), and DelKO (-m/+). The average litter
sizes of the one-day-old progeny are presented in each breeding setup.
RNA isolation and quantitative RT-PCR analysis
Total RNA was isolated from the brains of one-day-old neonates using a commercial kit
(Trizol, Invitrogen) according to the manufacturer’s protocol. The total RNA was then reversetranscribed using the M-MLV kit (Invitrogen), and the subsequent cDNA was used as a template
for quantitative PCR. This analysis was performed with SYBR Select Master Mix (Applied
Biosystems, Life Technologies) using the iCycler iQTM multicolor real-time detection system
(Bio-Rad). All qRT-PCR reactions were carried out for 40 cycles under standard PCR conditions
with internal controls (28S and β-actin). The results derived from qRT-PCR were further
analyzed using the threshold (Ct) value.
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Figure 2.2. Genotype and weight profiles of the breeding schemes. (A) Yy1 strain breeding
results. Representation of the male and female Yy1 hets and WT, observed in 6 litters of adult
mice. There was no significant difference observed between Yy1 hets versus WT offspring (X2
test: X2=0.091; df=1; p=0.7630), although a significant difference was observed between males
versus females in Yy1 hets (X2 test: X2=10.714; df=1; p=0.0011). (B) Graphical representation of
the genotype distribution (double het, Peg3 het, Yy1 het, and WT) for breeding I, II, and III
corresponding to CoKO paternal transmission, CoKO maternal transmission and DelKO paternal
transmission with Yy1 het, respectively. A total of 4 litters were used for this analysis consisting
of approximately 31 individuals for CoKO paternal transmission, 33 individuals for CoKO
maternal transmission, and 23 individuals for DelKO paternal transmission. (C) A graphical
representation of the weight distribution for all four genotypes observed from the breeding
schemes representing CoKO paternal transmission (blue), CoKO maternal transmission (pink),
and DelKO paternal transmission (purple). The percentage of birth weight for neonate mice was
calculated by comparing the individual weight at birth to the average weight of each litter for a
total of 4 litters. The error bars indicate the standard deviation observed between the birth weight
percentages among each genotype. CoKO paternal transmission weight comparison between
double heterozygous and wild-type neonates indicate a significant difference p=0.0121 using the
student t-test. CoKO maternal transmission weight comparison between double heterozygous
and wildtype neonates indicate a significant difference p=0.0094 using the student t-test. DelKO
paternal transmission neonate weight comparison between double heterozygous and wild-type
indicates no significant difference showing p=0.2595 using the student t-test. All two tailed pvalues have been calculated using the paired t-test.
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The experiments were performed in triplicates for each imprinted gene (Peg3, Zim1, Usp29). The
ΔCt value was initially calculated by subtracting Ct value of a testing replicate of a given gene
from the average Ct value of the internal control (28S and β-actin). The fold difference for each
replicate was then calculated by raising the ΔΔCt value as a power of 2 [29]. The relative
expression levels of all samples were then calculated by dividing the calculated expression level
of each sample by the expression level of the wild-type sample. The average and standard
deviation for each sample were then calculated by compiling the normalized values. The
information regarding individual primer sequences are also available (Table 2.2).
Table 2.2. Primer sets used for RT-PCR and qRT-PCR experiments.

Immunohistochemistry
Mice were deeply anesthetized with Nembutal (50mg/kg; i.p) and intracardially perfused
with 0.1 M sodium phosphate-buffered saline (PBS: pH 7.2-7.4) followed by a fixative of 4%
paraformaldehyde in 0.1 M phosphate buffer (PB: pH 7.2-7.4). Brains were dissected and postfixed in the same fixative overnight, then transferred to 30% sucrose in 0.1 M PB overnight.
Coronal sections (40-µm) containing the SON and PVN were obtained by a sliding microtome
(Leica SM2010R, Leica, Mannheim, Germany). Polyclonal antibody against PEG3 was raised in
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rabbit and used in free-floating brain slices overnight at 4°C at a concentration of 1:2,000 [16] in
PBS containing 0.5% Triton X-100 (PBST). For single staining of PEG3, the brain slices were
subsequently incubated with biotinylated goat anti-rabbit antibody (Vector Labs, Burlingame,
CA) at 1:200 in PBST. Antigen-antibody interaction was visualized by the ABCdiaminobenzidine method according to the protocol provided by Vector Labs (Burlingame, CA).
The brain sections were mounted on gelatin-coated slides, dehydrated, cleared and cover slipped
with Permount. The brain sections were rinsed 3 times for 5 min with PBST between each step.
For double immunofluorescence, the brain sections were incubated with PEG3 antibody,
followed by incubation with goat anti-rabbit antibody conjugated with DyLight 488 (Jackson
ImmunoResearch, West Grove, PA) at 1:400 in PBST overnight. Subsequently, sections were
incubated with either oxytocin-neurophysin (NP) or vasopressin-NP mouse monoclonal
antibodies (PS38 and PS41, respectively: provided by H. Gainer, NIH) at 1:500 in PBST
overnight, followed by incubation with goat anti-mouse antibody conjugated with DyLight 649
(Jackson ImmunoResearch, West Grove, PA) at 1:400 in PBST overnight. In some cases, brain
sections were counter stained with DNA labeling dye, 1,5-bis{(2-[di-methylamino)ethyl]amino}4, 8-dihydroxyanthracene-9,10-dione (DEAQ5), according to manufacture’s instructions
(BioStatus limited, Thermo Scientific). The sections were mounted in polyvinyl alcohol (PVA)
with anti-fading agent 1,4-diazabicyclo[2.2.2]octane (DABCO) that consists of 4.8g PVA, 12g
glycerol, 12mL dH2O, 24 mL0.2M Tris-HCl, and 1.25g DABCO. Images were acquired with a
confocal microscope Leica TCS SP2 spectral confocal microscope, Mannheim, Germany).
Optical section thickness was 1 µm. These were viewed in stacks of 5 sections using ImageJ
software (NIH).
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2.3 Results
Generation of mutant alleles for Peg3 and Yy1
The in vivo roles of Yy1 in the Peg3 domain were investigated using the following mutant
alleles, Peg3tm1aEUCOMMhmgu and Yy1tm2Yshi (Figure 2.3). First, the Peg3 locus was initially targeted
through inserting an expression cassette carrying a promoterless LacZ (β-galactosidase) and
NeoR (neomycin resistance gene) into its 5th intron [30].

Figure 2.3. Genomic structures of the wild-type and mutant alleles of Peg3 and Yy1. (A)
Schematic representation of the wild-type and mutant alleles of the mouse Peg3 locus. The 9
exons of Peg3 are indicated by closed boxes in the wild-type (WT) allele. The conditional
knockout (CoKO) allele has a 7.1-kb insertion containing a promoterless β-galactosidase (β-Gal)
and human β-actin promoter-driven neomycin resistant gene (NeoR). The insertion cassette in the
CoKO allele has been removed through FLP-mediated recombination, producing the FlipKO
allele. In the FlipKO allele, two LoxP sites flank the exon 6 of Peg3. The Cre recombinase has
been used for deleting the exon 6, deriving the DelKO allele for the Peg3 locus. (B) Schematic
representation of the wild-type and mutant alleles of the mouse Yy1 locus. The 1st exon of Yy1
has been deleted through Cre-mediated recombination, generating the mutant strain for Yy1.

32

In this knock-in/knock-out scheme, the 3’-side homologous hook contains two LoxP sites
flanking the exon 6, deriving a mutant allele that can be ready for conditional knockout
experiments. Thus, this mutant allele was named a conditional knockout-ready (CoKO) allele.
This CoKO allele was also designed to have immediate mutational effects through truncating the
transcription of Peg3 through two poly(A) signals that had been included as part of the inserted
cassette (Figure 2.3 A). The predicted mutational effects have been recently confirmed through a
study revealing the complete truncation and subsequent growth-related phenotypes among the
mutant mice carrying the CoKO allele [28]. The inserted cassette is also flanked by two FRT
sites, and thus the mutational effects by the CoKO allele can be rescued by FLP-mediated
recombination, deriving a reverted allele (FlipKO). Finally, the FlipKO allele can be mutated
again through the Cre-mediated recombination, resulting in the deletion of the exon 6 (DelKO).
Both the FlipKO and DelKO alleles have been successfully generated through two consecutive
but separate recombination events, and the mutant strains carrying these two alleles indeed
displayed the expected outcomes, the absence and presence of growth-related phenotypes,
respectively.
The mutant allele of the Yy1 locus has been derived from the floxed allele of Yy1 through
Cre-mediated recombination (Figure 2.3 B). This recombination deleted the 3.4-kb genomic
region encompassing the promoter and first exon of Yy1, abolishing the transcription and
translation of Yy1. According to the results from initial breeding experiments, the homozygotes
carrying the mutant allele were embryonic lethal, while the heterozygotes tend to exhibit smaller
body size than their wild-type littermates. This is consistent with the observations derived from
previous studies [27]. Interestingly, we have also observed a statistically significant gender ratio
among the heterozygotes (male : female = 18 : 3) (X2 test: X2=10.714; df=1; p=0.0011) although
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a small number of litters were tested (Figure 2.2 A). The females are less represented in the
heterozygous pool of neonates, which might be caused by Yy1 effects on the Xist locus. Overall,
3 different mutant alleles (CoKO, FlipKO, DelKO) for Peg3 and one mutant allele (Yy1 mutant)
for Yy1 were successfully generated for a series of breeding experiments as described below.
Breeding of CoKO and DelKO with Yy1 mutant stains
We used the following strategy to test the gene dosage effects of Yy1 on the Peg3 domain
in vivo (Figure 2.1). This strategy involves the crossing of the mutant alleles of two genetic loci,
Peg3 and Yy1, wherein the mutant alleles of Peg3 serve as a reporter to monitor the gene dosage
effects of Yy1. The CoKO allele expresses β-galactosidase (β-Gal) under the control of the
endogenous promoter of Peg3 so that potential Yy1 dosage effects on Peg3 can be inferred
through the activity of β-Gal or RT-PCR utilizing the sequence of β-Gal. Two parental alleles of
Peg3 are also functionally different due to genomic imprinting by the active paternal versus
repressed maternal alleles. Thus, Yy1 gene dosage effects on the paternal and maternal alleles of
Peg3 were analyzed separately through a set of reciprocal breeding schemes (Breeding I and II).
In Breeding I and II, the female and male heterozygotes (hets) for the mutant allele of Yy1 were
crossed with the male and female heterozygotes (hets) for the CoKO allele of Peg3, respectively.
We also used another mutant allele of Peg3, DelKO, as an independent reporter allele for this
experiment to rule out any artifacts that could originate from the inserted sequence elements
within the CoKO allele, such as β-Gal itself and human β-actin promoter-driven NeoR. Thus, the
female Yy1 hets were crossed with the male DelKO hets (Breeding III).
We have obtained four litters from each of the three breeding schemes, and examined
their litter sizes as well as individual health status by measuring their weights (Table 2.3 and
Figure 2.2 C). The litter sizes of one-day-old mice derived from breeding I, II, and III (8.25,
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7.75, and 6.5 respectively) were close to the normal litter size (8) of the same genetic
background (129/B6), indicating no embryonic lethality associated with these breeding schemes.
These three breeding schemes produced four different genotypes of the progeny: double hets
[Peg3+/-p Yy1-/+], Peg3 hets [Peg3+/-p], Yy1 hets [Yy1-/+], and wild-type [WT]. According to the
results from genotyping, all four different genotypes were represented at the predicted Mendelian
ratio (1: 1: 1: 1) among the progeny from the three breeding experiments, confirming that the
progeny with each genotype is viable until birth (Figure 2.2 B). This is again consistent with the
previous observation, that no embryonic lethality is associated with these breeding schemes. The
weight profiles, however, indicated that the double het progeny tend to be smaller and weaker
than their littermates (Figure 2.2 C). Furthermore, none of the double hets from breeding III
survived past their weaning age, indicating the severity of the combined mutational effects of
Yy1 and Peg3 on the postnatal survival of individual mice. In summary, the three breeding
schemes successfully produced the progeny with all possible combinations of genotypes.
Table 2.3. Summary of breeding results
Breeding results for experiments
Breeding
setup
I
II
III

Peg3 (+/-p)
Yy1 (-/+)
M
F
5
3
2
2

Peg3 (-m/+)
Yy1 (+/-)
M
F
2
7
-

Peg3 (+/-p)
M
6
3

F
1
5

Peg3 (-m/+)
M
3
-

F
7
-

Yy1 (-/+)
M
6
4
3

F
6
3
3

# of
litters

WT
M
3
2
4

F
3
3
2

4
4
4

Average
litter size
(adult)
8.25
7.75
6.25

Yy1 dosage effects on paternal allele of Peg3
The gene dosage effects of Yy1 on the Peg3 domain was analyzed mainly with the
progeny derived from Breeding III crossing female Yy1 hets and male Peg3 DelKO hets. A set
of one-day-old pups with four genotypes (double hets, Peg3 DelKO hets, Yy1 hets, WT) was
used for preparing total RNA, cDNA and subsequent qRT-PCR analyses (Figure 2.4).
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Figure 2.4. Effects of Yy1 gene dosage on the Peg3 imprinted domain. (A) Genomic structure of
the Peg3 imprinted domain: maternally expressed Zim1 and paternally expressed Peg3 and
Usp29. (B) The current study used two sets of RT-PCR primers for Peg3: the first set amplifying
exons 1-4 and the second set amplifying exons 3-6. (C) RT-PCR analyses of the progeny derived
from Breeding I (female Yy1 heterozygotes X male Peg3 DelKO heterozygotes). RT-PCR
amplifying exons 1-4 and exons 3-6 were performed using the total RNA isolated from the
neonatal brains with 4 genotypes (lanes 1-4). In the case of RT-PCR amplifying exons 1-4, the
PCR products from the pups with four genotypes represent the expression from the paternal
allele since Peg3 is paternally expressed. In the case of RT-PCR amplifying exons 3-6, the PCR
products from the pups with two genotypes (lane 3, Yy1-/+; lane 4, WT) still represent the
expression from the paternal allele of Peg3, but the products from the pups with the two other
genotypes (lane 1, Yy1-/+ Peg3+/-; lane 2, Peg3+/-) represent the expression from the maternal
allele. The mRNA from the paternal allele of Peg3, DelKO, cannot be detected by the RT-PCR
amplifying exons 3-6 since the exon 6 is deleted in the DelKO allele. (D) Quantitative RT-PCR
analyses using the total RNA isolated from the pups with four genotypes: Yy1-/+ Peg3+/- (1),
Peg3+/- (2), Yy1-/+ (3), WT (4). The expression values of each gene were normalized first with
an internal control (28S) and later with the values from the WT pup (lane 4). The expression
levels of Peg3 were analyzed using the primer set amplifying exons 1-4, thus representing the
expression levels of the paternal allele. This series of qRT-PCR analyses were repeated three
independent times from cDNA synthesis to qRT-PCR. Error bars indicate standard deviations for
observed triplicates.
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Actual dosage effects of Yy1 were tested by comparing the expression levels of a given gene
between double hets vs Peg3 DelKO hets (lane 1 vs 2 in Figure 2.4 C) and Yy1 hets vs WT (lane
3 vs 4 in Figure 2.4 C). For the Peg3 locus, two sets of primers were also used to measure the
expression levels, which included the primer set amplifying exon 1 through 4 for the paternal
allele and the primer set amplifying exon 3 through 6 for the maternal allele expression (Figure
2.4 B). Since the DelKO allele lacks exon 6, the primer set for exon 3-6 will amplify its
corresponding product only from the normal maternal allele that has been inherited from female
Yy1 hets. On the other hand, the primer set for exon 1-4 will amplify its product mainly from the
paternal allele due to the paternal expression of Peg3. This series of expression analyses also
included the two adjacent genes of Peg3, maternally expressed Zim1 and paternally expressed
Usp29 (Figure 2.4 A). Other imprinted genes, such as Zim2, Zim3 and Zfp264, were not included
due to their very low expression levels in neonatal brain [31, 32].
According to the results from qRT-PCR, the expression levels of the paternal allele of
Peg3 were 1.5-fold higher in double hets compared to Peg3 DelKO hets (lanes 1 and 2, Figure
2.4 D), and Yy1 hets compared to WT (lanes 3 and 4, Figure 2.4 D). In both sets, the half dosage
of Yy1 coincides with the up-regulation of Peg3, suggesting a repressor role for Yy1 in the
paternal allele of Peg3. Interestingly, the expression level of Peg3 is 3-folds lower in double hets
compared to Yy1 hets (lanes 1 and 3, Figure 2.4 D), and in Peg3 DelKO hets compared to WT
(lanes 2 and 4, Figure 2.4 D). This phenomenon is likely associated with exon 6 deletion in both
samples; thus, the observed down-regulation might be caused by the degradation of the Peg3
mRNA lacking exon 6 and thus the ORF (Open Reading Frame) through the NMD (Non-sense
mRNA Decay) pathway [33]. In the case of Zim1, the half dosage of Yy1 also correlates with the
up-regulation of Zim1, yet the levels of this up-regulation (16 fold) were much higher than those

37

observed from Peg3 (1.5 fold). By contrast, the half dosage of Yy1 did not result in any major
change in the expression levels of Usp29. Overall, this series of expression analyses concluded
that the half dosage of Yy1 coincides with the up-regulation of both Peg3 and Zim1, suggesting a
repressor role for Yy1 for both genes in the Peg3 imprinted domain. This series of analyses was
repeated with 3 technical replicates and 2 biological replicates, and the overall conclusion was
reproducible with these independent trials.
Yy1 dosage effect on maternal allele of Peg3
Yy1 dosage effects on the maternal allele of Peg3 were initially analyzed by detecting the
expression of β-Gal in the whole mount and sectioned samples prepared from the progeny of
Breeding II inheriting the CoKO allele with β-Gal maternally (Figure 2.1). Although this series
of experiments was not fruitful due to the low sensitivity of the β-Gal staining, we were able to
detect low levels of the maternal expression of Peg3 through RT-PCR (Figure 2.5 D). This
suggests that the paternal allele of Peg3 is intact and functional, and yet the maternal allele,
CoKO, is still expressed (Figure 2.5 D). To further investigate the observed maternal expression
of the Peg3 locus, we decided to use the progeny of Breeding III inheriting the DelKO allele
paternally, based on the following reason. The maternal allele in this progeny contains the
normal, unmodified Peg3 locus, yet it can be differentiated from the paternal DelKO allele
(lacking exon 6) with the primer set amplifying Peg3 exon 3-6 (Figure 2.5 A). According to the
initial survey (Figure 2.5 B), the low levels of Peg3 expression from the maternal allele were
indeed observed from the neonate brains among all progeny with the inherited DelKO allele
(Figure 2.5 C). This confirmed the maternal, and thus bi-allelic, expression of the Peg3 locus in
the brain. Subsequent qRT-PCR analyses further revealed that the relative expression level of the
maternal allele of Peg3 was about 0.5% of the paternal allele (Figure 2.5 F, G, Figure 2.6).
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Figure 2.5. Effects of Yy1 gene dosage on the maternal expression of Peg3. (A) Schematic
representation of the Peg3 locus showing the positions of the two sets of primers used for RTPCR. (B) RT-PCR products with the primer set amplifying exons 3-6. Comparison of the
expression levels between the neonate brains of pups with the following two genotypes, Yy1-/+;
Peg3+/- (lane 1) and Peg3+/- (lane 2), indicate up-regulation of the maternal allele of Peg3 by
the half dosage of Yy1. (C) Additional RT-PCR analyses further confirming the maternal
expression of Peg3 as well as up-regulation of the maternal expression of Peg3 by half dosage of
Yy1. Neonate brains of pups with the genotypes Yy1-/+ Peg3+/- (1), Peg3+/- (4), and WT (7) are
the same as the samples shown in Figure 2.5 B (2), (3), and (4), respectively. An additional set of
pups were obtained from Breeding III (marked with an asterisk *), and subsequently used for the
RT-PCR analyses. (D) Yy1 dosage effect on the maternal allele of Peg3. Additional RT-PCR
analyses confirming the maternal expression of Peg3 with an additional set of pups (1-7)
obtained from breeding II (CoKO maternal transmission with a half dosage of Yy1). The primer
set amplifying exon 1-4 was used to illustrate the paternal allele expression of Peg3, while the
primer set amplifying the β-Gal insertion cassette (exon 3 - β-Gal pseudo-exon) was used to
show the maternal allele expression of Peg3. (E) qRT-PCR analyses measuring the levels of the
paternal allele of Peg3 affected by the half dosage of Yy1. This analysis used the primer set
amplifying exons 1-4. (F) qRT-PCR analysis showing relative expression levels of the maternal
to paternal allele of Peg3. This analysis used the primer set amplifying exons 3-6. (G) qRT-PCR
analyses measuring the expression levels of the maternal allele of Peg3 affected by the half
dosage of Yy1. This analysis used the primer set amplifying exons 3-6.
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Figure 2.6. Maternal allele expression of Peg3 using a mouse hybrid cross. (A) Schematic
representation of the Peg3 locus. Positions are indicated for two sets of primers used for qRTPCR to distinguish the maternal and the paternal alleles of a PWD/B6 hybrid mouse strain. A
female PWD mouse was mated with a B6 male to give rise to hybrid progeny. Using two single
nucleotide polymorphisms (SNPs), two primers were designed to distinguish Peg3 alleles from
PWD (maternal) and the B6 (paternal). RNA was isolated and subsequent cDNA was generated
from the hypothalamus and the rest of the brain from PWD/B6 hybrid progeny to detect allele
specific Peg3 expression levels. (B) qRT-PCR analyses measuring the levels of Peg3 maternal
allele expression in PWD/B6 hypothalamus and brain compared to their parental strains. Allele
specific reverse primers were combined with a forward primer corresponding to Peg3 exon 6 to
amplify mRNA from Peg3 exon 6-9 to determine the relative expression levels of Peg3 in hybrid
tissues compared to their parental strains. The average expression levels of Peg3 was normalized
to β-actin and subsequently compared to B6 and PWD respectively. The percentage of maternal
Peg3 expression was calculated using the maternal to paternal expression ratio of the PWD/B6
hybrid tissues.
The half dosage of Yy1 also coincided with the 1.5-fold up-regulation of Peg3 (Figure 2.5 G),
which is similar to the up-regulation level seen in the paternal allele (Figure 2.5 E). Given the
similar changes of Peg3 expression levels observed between the paternal and maternal alleles by
a half dosage of Yy1, this is considered to be a transcriptional up-regulation of the already active
maternal allele, rather than de-repression of the repressed maternal allele by genomic imprinting
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(Figure 2.5). In summary, this series of analyses concluded that the maternal allele of Peg3 is
normally expressed at very low levels in the brain, and that the half dosage of Yy1 also causes an
up-regulation of Peg3 on the maternal allele.
Bi-allelic expression patterns in the specific areas of mouse brain
The observed low levels of expression from the maternal allele of Peg3 were further investigated
with RT-PCR (Figure 2.7) and immunohistochemistry. We first surveyed the maternal
expression of Peg3 using the total RNA isolated from the neonate mouse heads of the Peg3 het
mice inheriting the DelKO allele paternally (Figure 2.5 B, C). We repeated an RT-PCR assay on
a set of the total RNA isolated from the different parts of the adult mouse brain (Figure 2.7 A).

Figure 2.7. Maternal expression of Peg3 in mouse brain. (A) RT-PCR testing the maternal
expression of Peg3. The total RNA was isolated from the different parts of a 4-month-old male
mouse with the paternally transmitted DelKO allele (midbrain, cerebellum, olfactory,
hypothalamus, and pituitary). These RNA were analyzed with the two sets of primers amplifying
exon 1-4 and exon 3-6, confirming the maternal expression of Peg3 in the midbrain and
hypothalamus. (B) qRT-PCR analyses were also performed to measure the relative expression
levels of the paternal and maternal alleles of Peg3 between the RNA samples isolated from the
different parts of the adult brain, including the midbrain (M), cerebellum (C), olfactory (O),
hypothalamus (H), and pituitary (P). Parts of the adult mouse brain showing Peg3 maternal allele
expression have been marked with an asterisk (*).
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The maternal expression was detected mainly in the hypothalamus and mid brain sections with
the expression levels being slightly higher in the hypothalamus than in the mid brain (Figure 2.7
B). This was somewhat different from the expression pattern observed from the paternal allele,
which showed global expression throughout the entire brain. This suggests that the observed
maternal expression is specific to certain areas of the brain including the midbrain and the
hypothalamus regions. The relative expression levels of maternal to paternal alleles in these cell
types are much lower based on qRT-PCR data (about 1% of the paternal level, Figure 2.7 B,
Figure 2.6). This suggests that Peg3 expression is most likely bi-allelic in a small population of
cells in the midbrain and hypothalamus regions. Moreover, DNA methylation analyses using
DNA derived from tissues pertaining to bi-allelic expression shows no major methylation
differences when compared to tissues derived from other areas of the brain (Figure 2.8).

Figure 2.8. DNA Methylation analysis of Peg3. Methylation levels of the Peg3-DMR were
determined using COBRA. A set of genomic DNA isolated from the cortex and choroid plexus
of two mice (WT and Yy1-/+) was treated with bisulfite conversion. The amplified PCR products
from the Peg3-DMR were digested with HphI and TaqIa enzymes. The digestion pattern
revealed half methylation in both CP and CTRL without any major difference, indicating no
obvious methylation difference in the choroid plexus with Peg3 biallelic expression. This
suggests that small populations of cells are likely bialleleic and/or an unknown alterative
promoter may derive the maternal expression. The observed pattern is also true between WT and
YY1-/+, indicating no major effect on the biallelic expression of Peg3 by Yy1.
.
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To elucidate the location of maternal Peg3 expression in the brain, we performed
immunostaining of PEG3 using a series of whole coronal sections containing the hypothalamus
(10 sections collected every 200 µm) from an adult Peg3 hets inheriting the CoKO and DelKO
alleles paternally (Figure 2.9). Brain slices from the wild-type littermates were also included as a
positive control. There are numerous PEG3 immunoreactive cells ubiquitously located in the
brain sections from WT mice. The intensity of immunoreactivity appeared especially high in the
hypothalamic region (Figure 2.9 Aa) and in the choroid plexus in the lateral ventricles (Figure
2.9 Ba). In contrast, there was no detectable PEG3 immunoreactivity in the brain slices from the
paternally transmitted CoKO or DelKO mice, except in the hypothalamic paraventricular (PVN)
and supraoptic (SON) nuclei (Figure 2.9 Ab) and in the choroid plexus (Figure 2.9 Ba), which
was expected given the very low (0.5%) maternal expression of Peg3. Prominent PEG3immunoreactive cells observed in the PVN and SON in the CoKO and of DelKO mice (Figure
2.9 Ab) is also consistent with the results from RT-PCR, which showed Peg3 expression in the
hypothalamus (Figure 2.7 A, B). The choroid plexus is a tuft of capillaries with an overlaying
epithelial covering. PEG3 immunofluorescence labeling was counterstained with a DNA dye,
DRAQ5, to investigate whether PEG3 immunoreactivity is located in the capillary lining
enodothelial cells or the choroid plexus epithelial cells. PEG3 immunoreactivity was located
exclusively in the cuboidal epithelia typically found in the choroid plexus epithelium, but was
absent from the endothelia of the capillaries (Figure 2.9 Bb). Because the PVN and SON contain
neurons synthesizing neurohypophysial hormones, oxytocin and vasopressin, double
immunofluorescence detection of PEG3 and oxytocin/vasopressin was employed to determine
whether the maternal expression of Peg3 occurs specifically in oxytocin-and/or vasopressinsynthesizing neurons.
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Figure 2.9. PEG3 immunoreactivity in adult mouse hypothalamus. (A) PEG3 immunoreactivity
in the adult mouse hypothalamus of two littermates. Image a represents global PEG3
immunoreactivity in a 4-month-old, wild-type female mouse brain. Image b represents a 4month-old female mouse brain including the paternally transmitted DelKO allele with arrows
indicating PEG3 immunoreactive neurons located in the paraventricular nucleus (PVN) and the
supraoptic nucleus (SON). (B) PEG3 immunoreactivity of the maternal allele in the choroid
plexus from the paternally transmitted DelKO allele. Image a represents PEG3 immunoreactivity
of the choroid plexus located in the lateral ventricle. Image b represents immunoreactivity of
PEG3 (green) and DRAQ5 nuclear staining (blue), with a smaller arrow indicating PEG3
immunoreactive cuboidal choroid plexus epithelia, and a larger arrow indicating non-PEG3
immunoreactive endothelia of capillaries. (C) Double immunostaining of PEG3 (green) and
Oxytocin-OT/Vasopressin-VP (blue) immunoreactive neurons in the PVN from the paternally
transmitted DelKO allele. Overlay of PEG3/OT and PEG3/VP indicates PEG3
immunoreacitivity of the maternal allele coinciding predominantly with OT/VP immunoreactive
neurons in the PVN. (D) Double immunostaining of PEG3 (green) and OxytocinOT/Vasopressin-VP (blue) immunoreactive neurons in the SON from the paternally transmitted
DelKO allele. Overlay of PEG3/OT and PEG3/VP indicates PEG3 immunoreacitivity of the
maternal allele coinciding predominantly with OT/VP immunoreactive neurons in the SON.
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The double labeling revealed that PEG3-immunoreactivity was found in oxytocin- and
vasopressin- immunoreactive neurons in both the PVN (Figure 2.9 C) and SON (Figure 2.9 D).
In summary, this series of qRT-PCR and immunostaining experiments strongly suggest the
maternal allele expression of Peg3 in specific cell types of the mouse brain, thus confirming its
bi-allelic expression in these cell types.

2.4 Discussion
In the current study, we tested the in vivo effects of Yy1 gene dosage on the Peg3
imprinted domain with various breeding schemes utilizing the mutant alleles. The results
indicated that the half dosage of Yy1 coincides with the up-regulation of Peg3 and Zim1,
suggesting a repressor role of Yy1 in the imprinted domain. The results also posed an unexpected
observation that the maternal allele of Peg3 is normally expressed, and thus the expression of
Peg3 is bi-allelic in the specific areas of the brain, such as the choroid plexus and the SON and
PVN of the hypothalamus. Overall, these results confirm the in vivo repressor role of Yy1 that
had been previously observed from in vitro studies, and also provide a new insight regarding the
bi-allelic expression of Peg3 in the mouse brain.
According to the present study results (Figure 2.4), the half dosage of Yy1 appears to
coincide with the up-regulation of Peg3 and Zim1, suggesting a repressor role for Yy1 in the
Peg3 domain. A similar observation has been previously made multiple times through a series of
in vitro and in vivo experiments, demonstrating the global up-regulation of the Peg3 domain in a
response to the low levels of the YY1 protein [15-17]. This domain-wide response along with
multiple YY1 binding sites within the 1st intron of Peg3 have been the two major observations
suggesting the possibility that Yy1 is a major trans factor controlling the transcription of this 500-

45

kb domain [11]. This prediction is overall well supported by the current study utilizing much
more controlled in vivo systems than the previous in vitro systems [15-17]. Nevertheless, the
current study was unable to replicate another previous observation that the low levels of YY1
protein may be responsible for DNA hypomethylation on the Peg3-DMR (Figure 2.8). According
to the results (Figure 2.5), the half dosage of Yy1 does not appear to affect the epigenetic imprint
of the maternal allele of Peg3 although this is still somewhat inconclusive due to the technical
limitations associated with the sensitivity of the β-Gal staining. Instead, the boosted expression
levels observed from the maternal allele of Peg3 in Yy1 hets compared to those of WT mice is
thought to be caused by the up-regulation of the already active maternal allele, rather than by the
de-repression of the repressed maternal allele via DNA hypomethylation. Although we need to
further investigate this aspect in the near future, the inability to detect the predicted
hypomethylation in the current study could be due to the following reasons. First, half dosage of
Yy1 might not be sufficient enough to derive a similar observation made from in vitro studies.
Second, the pups severely affected by the DNA hypomethylation might not be viable so that the
breeding schemes used for the current study could not produce the pups with predicted
epigenetic imprints. Overall, the current study utilizing in vivo systems again confirms that Yy1
functions as a transcriptional repressor for the Peg3 imprinted domain.
Given the fact that one allele of Peg3 is already repressed by genomic imprinting, it is
interesting to speculate why the remaining active allele requires further repression by another
transcription factor, Yy1. This may be related to the potential functions of Peg3. According to the
recent studies, Peg3 is predicted to be a major regulator controlling autophagy in endothelial
cells [34, 35]. Many stimuli from environment, such as starvation, can stimulate autophagy along
with Peg3, resulting in a temporal up-regulation of Peg3. Restoring it back to normal levels of
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Peg3 is likely required for the proper function of cells, which may use other unknown regulatory
mechanisms. In that regard, it is relevant to note that the mTOR (mechanistic target of
rapamycin) signaling pathway is known to repress autophagy, in which Yy1 acts as a major
contributing factor [36]. Thus, it is reasonable to predict that Yy1 may be involved in controlling
the dynamically fluctuating levels of Peg3, which may be triggered by environmental and
developmental cues. Recent studies on histone modification profiles have also indicated that
promoters of several imprinted genes in the Peg3 domain interacts with one evolutionarily
conserved region, ECR18, suggesting its key roles played in the transcription and imprinting
control of Peg3 domain as a distant regulatory element [37]. Thus, it is conceivable that Yy1 may
affect histone modification profiles contributing to the up-regulation of Peg3 expression instead
of DNA methylation changes, using such distant regulatory elements. Although speculative, this
may be a reason why Yy1 is needed for the repression of Peg3, which requires further
investigation in near future.
The expression of Peg3 appears to be bi-allelic in the specific areas of the brain (Figures
2.7, 2.9). The detection of the maternal expression of Peg3 from the both mutant models, CoKO
and DelKO, rules out the possibility that this detection is due to unknown artifacts associated
with mutagenesis. Also, this rules out the possibility that the observed maternal expression of
Peg3 is caused by some functional compensation between two parental alleles. For instance, the
loss-of-function type mutation on the paternal allele (DelKO) might render the cells to de-repress
the repressed maternal allele. In the case of the progeny inheriting the CoKO allele maternally
(Figure 2.1), however, the paternal allele of Peg3 is intact and functional, and yet the maternal
allele, CoKO, is still expressed (Figure 2.5 D). Therefore, this strongly supports the idea that the
observed maternal expression is reflecting the genuine bi-allelic expression of Peg3 in normal
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mice, which has been previously unnoticed. Nevertheless, this new observation is intriguing
given the following reasons. First, there is another imprinted gene, Igf2, which is known to be biallelic in the choroid plexus [38, 39]. Given a very small number of imprinted genes in
mammalian genomes, the bi-allelic expression of two imprinted genes (Peg3 and Igf2) in the
same small area of mouse brain seems to be a very rare coincidence. At the same time, the
choroid plexus is known to play a major role in controlling the concentration of ions such as Na+,
Cl-, HCO3-, and K+ in the cerebrospinal fluid, and thus should be very critical for the normal
function of neurons in the brain. Thus, this rare coincidence may be an indication that some
functional constraints derive the bi-allelic expression of these two imprinted genes in the choroid
plexus. Second, several previous reports have predicted that the maternal allele of Peg3 may be
functional at some unknown stages and/or in specific cell types since the homozygous animals
for several mutant alleles targeting the Peg3 locus are not viable although the paternal
heterozygotes are still viable [18, 28]. This prediction is further supported by the observed biallelic expression of Peg3 in that the maternal allele of Peg3 is indeed expressed and functional
in the specific areas of brains. The lack of both the paternal and maternal expression of Peg3 in
these brain areas might contribute to the observed lethality of the homozygous mutant animals.
Although this is likely, we need to first investigate the functional contribution of the maternal
allele of Peg3 to the choroid plexus and other areas, such as the PVN and SON of hypothalamus.
Overall, the current study reports, for the first time, the bi-allelic expression of Peg3 in specific
areas of mouse brain, and thus it would be of great interest to follow up the functional
significance of the observed bi-allelic expression in the near future.
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CHAPTER 3
ALTERNATIVE PROMOTERS OF PEG3 WITH MATERNAL SPECIFICITY 2

3.1 Introduction
Peg3 (paternally expressed gene 3) is the first imprinted gene identified from an
evolutionarily conserved 500-kb domain localized in human chromosome 19q13.4 and mouse
proximal chromosome 7 [1-3]. This domain harbors 6 additional imprinted genes: the paternally
expressed Usp29, Zfp264, and APeg3, and the maternally expressed Zim1, Zim2, and Zim3 [4-7].
Peg3 is structurally comprised of 9 exons that are spread over a 25-kb distance in both human
and mouse. Interestingly, the 200-kb upstream region of both human and mouse PEG3 lacks any
obvious ORF (Open Reading Frame), but this region has been well preserved during mammalian
evolution. According to recent studies, this 200-kb region is filled with small ECRs
(Evolutionarily Conserved Regions), which are putative cis-regulatory elements for Peg3 and
other imprinted genes [8, 9]. Peg3 has been shown to be involved in controlling maternal-caring
behaviors and fetal growth rates [10]. Accordingly, Peg3 is highly expressed in neuronal cells as
well as embryos and placentas [3, 11]. The mechanistic basis for these expression patterns and
also the paternal-specific expression of Peg3 is still under investigation. Nevertheless, the
potential cis-regulatory elements found within the 200-kb region are hypothesized to be involved
in regulating the tissue- and allele-specific expression patterns of Peg3, given their unusual
evolutionary conservation.
As seen in the Peg3 locus, other imprinted domains also have similar unusual genomic
layouts. For instance, the upstream region of human and mouse SNRPN is more than 500 kb in
2

This chapter previously appeared as Perera, B. P. U., Teruyama, R., and Kim, J. (2016)
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length, which is relatively large compared to a 20-kb transcribed area from its coding region.
This 500-kb region also lacks any obvious ORFs, but this region harbors multiple alternative
promoters for Snrpn and Ube3a-ATS, an antisense transcript gene to Ube3a [12]. In fact, some of
these alternative promoters are critical for establishing germline-specific DNA methylation
marks [13, 14]. A similar case has been observed from the Gnas domain, where the transcription
of the locus is driven by multiple alternative promoters of various tissue and allele specificity
[15, 16]. Yet, the transcription by one particular promoter during oogenesis is believed to be
responsible for establishing oocyte-specific DNA methylation marks for the downstream
promoter [17]. There are additional cases of imprinted domains that harbor multiple alternative
promoters in their large upstream regions include Zac1 and Grb10. In the Zac1 locus, the
multiple promoters are responsible for its various tissue-specific expression patterns [17-19]. On
the other hand, the two alternative promoters of Grb10 are known to display both allele and
tissue specificity [20, 21]. Given these examples, it is reasonable to predict that the 200-kb
upstream region of the Peg3 locus may also have similar alternative promoters, although the
Peg3 locus has long been known to have only one promoter in both human and mouse.
A recent study, however, demonstrated that the expression of Peg3 appears to be biallelic in certain areas of the adult mouse brain, such as the hypothalamus and choroid plexus
[22]. This may be an indicator for either de-repression of the maternal allele of the known
promoter or the presence of potential alternative promoters for the Peg3 locus. In the current
study, therefore, we sought to characterize the observed bi-allelic expression pattern with a
strategy involving 5’RACE and NGS-based (Next Generation Sequencing) deep sequencing
experiments. With this approach, we were able to identify several alternative promoters for both
human and mouse PEG3. A series of expression analyses further revealed that these alternative
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promoters display allele-, tissue-, and stage-specific expression patterns. More detailed results
are described in the following section.

3.2 Materials and Methods
Generating the mutant strains for Peg3
The The current study used the KO2 and DelKO mutant mouse strains derived from
KO2-Neo and CoKO strains, respectively. The strain for the CoKO allele of Peg3 was made
using a targeted ES cell from the EUCOMM (European Conditional Mouse Mutagenesis
program), and this strain has been maintained in the lab [23]. The strain for the KO2-Neo allele
of Peg3 was made using the targeted ES cells from Darwin Transgenic Mouse Core Facility of
Baylor College of Medicine, and this strain has been maintained in the lab (H. He et al,
unpublished). The CoKO mouse strain was crossed with the Rosa26-FLP line from Jackson Lab
(Stock No. 009086, B6.129S4-Gt (ROSA)26Sortm1(FLP1)Dym/RainJ) to allow for FLP-mediated
recombination, generating the FlipKO allele. Both the FlipKO and KO2-Neo strains were
crossed with the Zp3-Cre line from the Jackson Lab (Stock No. 003651, C57BL/6-Tg (Zp3-cre)
93Knw/J). The mutagenesis through these breeding derived the DelKO and KO2 strains for the
Peg3 locus [22, 24]. The following primer sets were used for genotyping of these strains: the
deletion and detection of the expression cassette for FlipKO, Peg3-CoKO-F (5’ATGAGTCTCGATCCAGGTATGCC-3’)

and

TGAACTGATGGCGAGCTCAGACC-3’),

LoxR

(5’-

Peg3-5arm

CCCTCAGCAGAGCTGTTTCCTGCC-3’)

and

(5’-

Peg3-Lar3

(5’-

CAACGGGTTCTTCTGTTAGTCC-3’); the deletion and detection of the expression cassette for
DelKO,

Peg3-5arm

(5’-CCCTCAGCAGAGCTGTTTCCTGCC-3’)
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and

LoxR

(5’-

TGAACTGATGGCGAGCTCAGACC-3’),

Peg3-5arm

CCCTCAGCAGAGCTGTTTCCTGCC-3’)

and

(5’-

Peg3-rev

(5’-

ACCCCATTCTCATCAGCTCCAGAG-3’), the deletion of exon 1 for Peg3 and Usp29,
bac2082-F

(5’-ACAACCCGGAGTTTTAGCAGAC-3’)

GGATGTAAGATGGAGGCACTGT-3’);

the

TAGGAATCACGTGGAGTGTCT-3’)

presence
and

and
of

bac6710-R

Zp3-Cre,
oIMR1085

Zp3-cre-F

(5’(5’(5’-

GTGAAACAGCATTGCTGTCACTT-3’). DNA was isolated from ear or tail snips after
incubating the tissues at 65°C with the tail lysis buffer (50 mM Tris-Cl at pH 8.0, 100 mM
EDTA at pH 8.0, 250 mM NaCl, 1% SDS, 20 µg/mL Proteinase K). PCR premix kit (Intron
Biotech) was used for genotyping at the following conditions (step 1, 95°C-2 min; step 2, 95°C30 sec, 60°C-30 sec, 72°C-60 sec for 33 cycles; step 3, 72°C-7 min). The information regarding
individual primer sequences is also available (Table 3.1). All animal studies were approved by
the Louisiana State University Institutional Animal Care and Use Committee (IACUC) and were
performed in accordance with approved guidelines and regulations of the LSU Division of
Laboratory Animal Medicine, Baton Rouge, Louisiana, U.S.A.
Table 3.1 Primer sets used for genotyping, 5’RACE, RT-PCR, and DNA methylation analyses
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Table 3.1 continued

5’ RACE and sequencing
Total RNAs were isolated from adult mouse hypothalamus and one-day-old mouse
neonate heads using the Trizol RNA isolation kit (Invitrogen). Total RNAs for normal adult and
neonate human brains were purchased from BioChain (cat: R1234035-50; R1244035-50). The
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total RNA (2.5-5µg) was mixed with gene-specific primers substituting random primers: Ex2-R1
(5’-AGTCTTCCTCTTGCCAGTTGTC-3’)

for

KO2

CCAAAATGTGGTCTTGACATCACAG-3’)

for

DelKO

mice,
mice,

Ex6-R2
and

Ex2-R1

(5’(5'-

TCCCTCTTCCTCTCGCCAGTCG-3') for human, and reverse-transcribed using the M-MuLV
reverse transcriptase (New England Biolabs, cat: M0253S). The cDNA products were purified
using phenol chloroform extraction and ethanol precipitation. The 5′-ends of the purified cDNA
were further modified by the tailing reaction using dGTPs and terminal deoxynucleotidyl
transferase according to the manufacturer’s protocol (New England Biolabs, cat: M0315S). The
tailed

cDNA

was

amplified

using

two

primers:

the

tail

long

primer

(5′-

GGTTGTGAGCTCTTCTAGATCCCCCCCCCCCCNN-3′) and internal gene-specific primers:
Ex2-R2

(5’-TCCTCTTGCCAGTTGTCTCCAA-3’)

ATGTGGTCTTGACATCACAGGAAGA-3’)

for

for
DelKO

KO2
mice,

mice,

Ex6-R3

(5’-

and

Ex2-R2

(5'-

CTTCCTCTCGCCAGTCGTCTCC-3') for human. The amplified DNA was re-amplified with a
set of nested primers: the tail out primer (5′-GGTTGTGAGCTCTTCTAGA-3′) and additional
internal gene-specific primers as anchors (Table 3.1). The PCR products were further purified
and sequenced using next generation sequencing (NGS) for analysis of 5’ RACE products [25].
RNA isolation and quantitative RT-PCR analysis
Total RNA was isolated from the olfactory bulb, midbrain, hypothalamus, cerebellum,
thymus, heart, lung, liver, kidney, fat, testis, 14.5-dpc placenta and ovary from adult male and
female mice, heads of one-day-old neonates, and 14.5-dpc embryos using a commercial kit
(Trizol reagent, Life technologies, cat: 15596018) according to the manufacturer’s protocol.
Total RNAs for normal human adult brain and the neonate brain were purchased from BioChain
(cat: R1234035-50; R1244035-50). The total RNA was then reverse-transcribed using the M57

MuLV reverse transcriptase (NEB, cat: M0253S). A set of normalized cDNA for human heart,
liver, kidney, and placenta was obtained from BioChain as well. The cDNA fragments were used
as a template for PCR amplification (Maxime PCR Premix Kit, Intron Biotech) to check for
mRNA transcripts at the following conditions (step 1, 95°C-2 min; step 2, 95°C-30 sec, 60°C-30
sec, 72°C-60 sec for 36 cycles; step 3, 72°C-7 min). The information regarding individual primer
sequences is also available (Table 3.1).
DNA methylation analysis
DNA was first isolated from the hypothalamus, olfactory bulb, midbrain, cerebellum, and
kidney of WT adult mice, and subsequently treated with the bisulfite conversion protocol using
the EZ DNA methylation kit (Zymo Research, cat: D5002). The converted DNA was used for
PCR amplification of the upstream exons regions E1, U1, U2, and U3 (Maxime PCR Premix Kit,
Intron Biotech). The following primer combination was used to amplify the upstream U1
promoter: Bis-Peg3-RACEF1-F1 (5’- GTTGGGAATGGAAAGTTTAAAGATAAA -3’) and
Bis-Peg3-RACEF1-R1 (5'- AAAATCAAAACTACACCAAACATACAAC -3'). Upstream U2
promoter was amplified by using the following primer combination: ECR4-Bis-a (5’ATTGGTTTATAGTTAGGGAAGGAAGTAGT

-3’)

and

ECR4-Bis-b

(5'-

AAATCTCTCTAAAACATAATACTATTCTAT -3'). The following primer combination was
used

to

amplify

the

upstream

U3

GTAGGTAGATAATTTATTGGATAAAGAGTT

promoter:

Bis-Peg3-RACEF5-F

(5'-

-3')

Bis-Peg3-RACEF5-R

(5'-

and

CTTTCTTTCTCTCTTTCTTTATACATATAT -3'). The upstream E1 promoter was amplified
by

using

the

following

primer

combination:

GTTTTTGTAGAGGATTTTGATAAGGAG

-3’)

and

mPeg3-pro-bis-a.1

(5’-

mPeg3-pro-bis-b

(5'-

CACCCCAAACACCATCTAAACTCTACAAAC -3'). Each PCR product was further analyzed
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by restriction enzyme digestion-based COBRA (COmbined Bisulfite Restriction Assay) and
sequencing [26, 27]. For the COBRA analysis, PCR products were digested with various
restriction enzymes (NEB). Each PCR product was also used for next-generation sequencing
(NGS). Detailed information regarding oligonucleotide sequences, and COBRA is also available
(Table 3.1).

3.3 Results
Mutant alleles of Peg3
In the current study, two mutant alleles of mouse Peg3 were used to identify the
alternative 1st exons and corresponding promoters that may be localized upstream of the known
1st exon and promoter of Peg3. The known 1st exon of Peg3 is localized next to the 1st exon of
the adjacent gene Usp29, controlling the transcription of both Peg3 and Usp29 bidirectionally
(Figure 3.1 A). The 4-kb genomic region surrounding this bidirectional promoter is also
differentially methylated between two alleles: unmethylated paternal versus methylated maternal
alleles [8]. Thus, this promoter is functional only from the paternal allele. This 4-kb DMR of
Peg3 was deleted using a floxed allele recently generated in the lab named KO2-Neo (H. He et
al, unpublished). The Zp3-cre strain involves a cre-recombinase enzyme that is expressed in the
female germ line. When bred with the KO2-Neo strain, the floxed sequence is recognized and
deleted in the growing oocytes. Thus, generating the KO2 allele with a deletion of the known
Peg3 promoter region including its first exon (Figure 3.1 B, C). The current study also used
another strain, CoKO, which is designed to truncate the transcription of Peg3 and also to delete
the exon 6 with two flanking LoxP sites [23]. This CoKO strain was first bred with the Flippase
strain, and later with the Zp3-cre strain to delete exon 6, generating the second mutant allele
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DelKO for the current study (Figure 3.1 C). Since Peg3 is expressed mainly from the paternal
allele, the two mutant alleles were transmitted paternally to remove the main transcript of Peg3
for the KO2 strain and also to have the main transcript without exon 6 for the DelKO strain [24].

Figure 3.1. Genomic structures of the wild-type and mutant alleles of Peg3. (A) Schematic
representation of the wild-type alleles of mouse Usp29 and Peg3 loci. Gray and black boxes
indicate the exons of Usp29 and Peg3, respectively. Transcriptional direction for each gene is
represented by arrows with corresponding colors. (B) Schematic representation of the KO2
mutant allele. The KO2-Neo mutant has a 6.0-kb insertion containing a PGK promoter-driven
neomycin resistance gene (NeoR) as selection marker, shown by the red box. NeoR, along with
the 4.0-kb promoter region of Peg3 containing first exons of Usp29 and Peg3 are flanked by two
LoxP sites as indicated with triangles. Cre-recombinase was used to delete the first exons of
Usp29 and Peg3, producing the KO2 mutant. (C) Schematic representation of the DelKO mutant
allele. The conditional-ready knockout (CoKO) allele has a 7.1-kb insertion containing a
promoterless β-galactosidase gene (β-Gal) as shown by the blue box and human β-actin
promoter-driven neomycin resistance gene (NeoR) as shown by the red box. The insertion
cassette of the CoKO allele is removed by FLP-mediated recombination, producing the FlipKO
allele which has the 6th exon of Peg3 flanked by two LoxP sites as indicated with triangles. Cre
recombinase was used to delete exon 6, producing the DelKO allele for the Peg3 locus.
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Alternative 1st exons and promoters of Peg3
To identify potential alternative 1st exons of Peg3, a series of 5’RACE (Rapid
Amplification cDNA Ends) experiments were performed using total RNA isolated from the
tissues of the two mutant strains and their wild-type littermates (Figure 3.2 A). Total RNA was
isolated from the brains of neonates given that high levels of Peg3 expression were found in
neuronal cells 3. The hypothalamus of adult mice has already shown maternal expression of
Peg3, suggesting the presence of potential alternative promoters for Peg3 [22]. Thus, this portion
of brain was also included for the current study. The total RNA from the neonatal brains and the
adult hypothalamus were first reverse-transcribed with gene-specific primers: Ex2-R1 for the
total RNA from KO2(+/-p) and Ex6-R1 for the total RNA from DelKO(+/-p). These initial cDNA
fragments generated by Ex2-R1 and Ex6-R1 primers were further amplified using two different
nested PCR schemes (RACE I and II, Figure 3.2 A). The amplified libraries were finally
sequenced using a NGS (Next Generation Sequencing) platform [25], and the results are
summarized in Table 3.2.
Table 3.2. Summary of NGS-based sequencing of 5’RACE libraries from mouse Peg3
% of specific reads for different transcripts
Tissues
(genotype)

Neonatal brain
(KO2)

Neonatal brain
(WT)

Neonatal brain
(WT)

Adult hypoth
(DelKO)

RACE scheme
(# of total read)

I
(575)

I
(1843)

II
(5473)

II
(1197)

E1-E2-9

6.60

93.54

-

-

U1-U0-E2-9

0.00

0.00

8.17

78.96

U2-U0-E2-9

67.83

0.33

77.96

0.00

U3-U0-E2-9

0.00

0.00

0.09

7.60
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Figure 3.2. Alternative 1st exons and promoters of Peg3. (A) Map of the mouse Peg3 locus. Gray
and black boxes indicate the exons of Usp29 and Peg3, respectively. Transcriptional direction
for each gene is represented by arrows with corresponding colors. The solid boxes indicate the
position of the exons of Peg3, labeled E1 through E9, followed by ovals to indicate the position
of upstream alternative exons. The closed oval represents the shared upstream exon U0, and open
ovals represent alternative 1st exons U1, U2, and U3, respectively. The deleted Peg3 exons
corresponding to KO2(+/-p) and DelKO(+/-p) mutant alleles are shown using parentheses and
dashed lines. The two extended arrows show the anchoring primers used for nested PCR after 5’
RACE: Ex2-R2 and Ex2-R3 for KO2(+/-p) mutant and its WT counterpart, as shown by scheme I.
The two extended arrows underneath it shows the anchoring primers used for nested PCR after
5’ RACE: Ex6-R3 and U0 for DelKO(+/-p) adult hypothalamus and a WT neonate brain as
indicated by the scheme II. A summary of the sequence reads is shown in Table 3.2. (B) The
exon structures of Peg3 alternative transcripts identified from the mouse brain. The E1 - E2 exon
structure indicates the transcription by the main promoter of Peg3. The exon U1 is positioned 20kb upstream of E1, the 1st exon of Peg3. The alternative transcript starting from the U1 exon
connects to U0 (16-kb upstream of E1) and E2 exons while skipping E1. The exon U2 is
positioned 26-kb upstream of E1. This alternative transcript starting from the U2 exon connects
to U0 and E2 exons while skipping U1 and E1 exons. The exon U3 is positioned 163-kb
upstream of E1. The alternative transcript starting from the U3 exon connects to U0 and E2
exons while skipping U2, U1 and E1 exons. Genomic distances are not drawn to scale.
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Inspection of the sequence reads from four individual libraries provided the following
conclusions (Table 3.2). First, detailed analyses confirmed the presence of four new upstream
exons, thus named U0 through U3. The genomic positions of these exons relative to that of the
known 1st exon (E1) are as follows: U3 (163 kb), U2 (26 kb), U1 (20 kb) and U0 (16 kb
upstream of E1). These upstream exons are spread throughout the middle 200-kb genomic region
of the Peg3 imprinted domain, which is quite unexpected and remarkable, as the previously
identified exons of Peg3, E1-E9, spans only a 25-kb genomic distance (Figure 3.2 B). Second,
the three exons U1, U2, and U3 have a clear exon-intron border at their 3’-ends, but not at the 5’ends, suggesting that the 5’-end of these exons likely contain transcription start sites. This further
suggests that the immediate upstream regions of these three exons should serve as alternative
promoters for the Peg3 locus. This is also the case for E1 exon, which has long been known as
the 1st exon for the Peg3 locus. On the other hand, U0 exon has a clear exon-intron border in
either end, suggesting that this exon is likely connected downstream to the transcripts that start
from its upstream regions starting from U1, U2, and U3. None of the transcripts starting from its
upstream regions, U1, U2 and U3, are connected to E1. Instead, they all skip the E1 exon, and
are directly connected to the E2 exon. This agrees with the fact that the 5’-end sequence of E1
contains a promoter and transcription start site, but not a splicing acceptor site. The exon
structures of these newly identified transcripts are summarized in Figure 3.2 B.
Third, the newly identified transcripts U1, U2, and U3 all appear to contain a proper
combination of the previously identified downstream exons of Peg3, including E2 through E6,
based on a subset of the long sequence reads that had been derived from the libraries. Thus, we
performed an independent series of RT-PCR experiments to determine the extent of the
transcripts starting from U1, U2 and U3, particularly focusing on the 3’-ends of these transcripts.
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These analyses confirmed that all the transcripts starting from U1, U2 and U3 indeed contain
properly spliced downstream exons, including E2 through E9 (Figure 3.3).

Figure 3.3. RT-PCR analysis of alternative exons in the mouse brain. (A) A schematic of the
mouse Peg3 locus with RT-PCR primer combinations. Gray and black boxes indicate the exons
of Usp29 and Peg3, respectively. The red arrows indicate the directionality of primers: E9-R
coupled with E1, U0, U1, U2, and U3 specific primers to amplify the respective exons. The
deleted Peg3 exons corresponding to KO2(+/-p) and DelKO(+/-p) mutant alleles are shown
using parentheses and dashed lines. The RT-PCR panel indicates the expression patterns of Peg3
using total RNA isolated from DelKO(+/-p) adult hypothalamus and KO2(+/- p) neonate brain
tissues. The U3, U2, and U1 represent primer combinations targeting the upstream 1st exons of
Peg3 with E9-R primer combination; U0 targets a shared upstream exon of Peg3 with the E9-R
primer, while E1 targets the main promoter of Peg3 with the E9-R primer, to show the
expression profile preferred by each exon. (B) Genotyping of the paternally transmitted KO2
allele. The schematic represents the mouse locus for the paternal and maternal alleles of Peg3.
The arrows indicate the primer combinations used for PCR amplification. The dotted box
represents the deleted region corresponding to the bidirectional promoter. (C) Structural map of
the upstream alternative exons of Peg3. The blue rectangles represent Peg3, Usp29, and APeg3
exon structures within the 6658776-6703943 genomic region of mouse chromosomes 7, with
arrows indicating the respective transcriptional directions. The U0-E9 exon structure represents
the genomic region transcribed by the shared upstream alternative exon of Peg3, with arrows
indicating its transcriptional direction. The UCSC genome browser was used to visualize the
exon structure of U0-E9.
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Since the known ORF (Open Reading Frame) of Peg3 spans from E3 through E9, this further
suggests that these transcripts may serve as mRNA templates that produce the PEG3 protein.
Fourth, each of the identified transcripts was represented differently compared to the other
transcripts in the four libraries of 5’RACE products based on the number of its sequence reads
(Table 3.2). The U2 represented the highest amount of transcripts (77%, 4267/5473), followed
by U1 (8.17%, 447/5473) and U3 (0.09%, 5/5473), according to the results from the third library
that had been derived from the WT neonatal brain. The remaining 14.7% (754/5473) products
were non-specific sequence reads. This trend was also true for two other libraries derived from
neonates, with U2 transcript showing the highest percentage among the newly identified
transcripts. Interestingly, this was not the case in the library derived from the hypothalamus of
the adult DelKO mice (Table 3.2, Figure 3.4). Instead, U2 transcript was not detected at all while
the remaining U1 and U3 transcripts were well represented. It is relevant to note that the tissue
source of this library was the adult hypothalamus, rather than the neonate brain, which was used
for the other three libraries. Thus, U2 transcript might be neonatal-specific, which was further
tested in the following section (Figure 3.5). On a different note, the relative representation of U2
transcript to the known main transcript (E1-E9) was 0.33 to 93%, indicating that the three
identified transcripts are overall very minor compared to the primary transcript starting from E1,
as shown by the results from the second library. Since these alternative transcripts were also
detected from the wild-type animals, they likely represent the genuine transcripts of Peg3 rather
than potential artifacts that could be generated as an outcome of knockout mutations. Scheme I
and scheme II (Table 3.2) are different in terms of the gene-specific primers used for the
respective nested PCR scheme as shown by Figure 2. Even in the case of Scheme II, two
different nested primers were also used between two different libraries: a shared upstream exon
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(U0) as an anchor for the DelKO and WT tissues (Table 3.2) versus the exon 4 as an anchor for
the hypothalamus of adult DelKO (Figure 3.4 B). Thus, comparison of the results from these two
schemes needs a caution. Taken together, this series of 5’RACE and NGS sequencing confirmed
that the Peg3 locus harbors three alternative 1st exons and promoters that have never been
previously described. The three alternative 1st exons and promoters are distributed throughout a
relatively large genomic interval (the middle 200-kb region of the Peg3 imprinted domain),
which as of yet has not been well characterized.

Figure 3.4. Alternative transcripts determined by 5’ RACE. (A) Map of the mouse Peg3 locus.
Gray and black boxes indicate the exons of Usp29 and Peg3, respectively. Transcriptional
direction for each gene is represented using arrows with corresponding colors. A solid red arrow
indicates the position of the first exon of Peg3, labeled E1, followed by dotted arrows to indicate
the position of upstream alternative exons. The ovals represent upstream exons U0, U1, U2, and
U3, respectively. The extended arrow shows the gene-specific primer Ex6-R2 used for
DelKO(+/-p) mouse hypothalamus cDNA synthesis. (B) Percentage of Peg3 alternative
transcripts identified from adult mouse hypothalamus. The Ex12,4 indicates the anchoring
primer used for nested PCR. The percentage of transcripts preferred by DelKO(+/-p) adult mouse
hypothalamus was calculated by counting the sequences specific for E1,U0, U1, U2, and U3.

66

Allele and tissue specificity of the alternative promoters of Peg3
The three alternative transcripts of Peg3 were further characterized in terms of their allele
and tissue specificity using RT-PCR experiments (Figure 3.5).

Figure 3.5. Allele and tissue specificity of the alternative transcripts of Peg3. (A) A schematic of
the mouse Peg3 locus with RT-PCR primer combinations. Gray and black boxes indicate the
exons of Usp29 and Peg3, respectively. The transcriptional direction for each gene is represented
with arrows and corresponding colors above the map. The arrows below the map indicate the
directionality of primers: Peg3-RT-Ex6-R3 was coupled with U0, U1, U2, and U3 specific
primers to amplify the respective alternative exons. The DelKO(+/-p) mutant has a deletion on
exon 6 of the Peg3 paternal allele, enabling the detection of its maternal allele expression.
Similarly, the DelKO(-m/+) mutant has a deletion on exon 6 of the Peg3 maternal allele, enabling
the detection of Peg3 paternal allele expression. (B) Allele, tissue, and stage specificity of
upstream alternative promoters of Peg3. The left RT-PCR panel shows the maternal expression
patterns of the identified alternative promoters using total RNA isolated from tissues of
DelKO(+/-p) mice: OB (olfactory bulb), MB (midbrain), HT (hypothalamus), CB (cerebellum),
TM (thymus), HR (heart), LG (lung), LV (liver), KD (kidney), FT (fat), TT (testis), OV (ovary),
and NB (neonate head). The right RT-PCR panel shows the paternal expression patterns using
total RNA isolated from tissues of DelKO(-m/+) mice: OB (olfactory bulb), MB (midbrain), HT
(hypothalamus), CB (cerebellum), and NB (neonate head). The U3-Ex6R3, U2-Ex6R3, and U1Ex6R3 primer combinations amplified the upstream alternative 1st exons of Peg3, whereas U0Ex6R3 primer combination amplified a shared upstream exon of Peg3 to show the expression
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profile preferred by each upstream exon. The combination of exon 1 and exon 2 primers was
used to explore the expression pattern of Usp29. Equal amounts of total RNA were used for RTPCR, which were further normalized and visualized by β-actin expression levels. We repeated
this analysis using three independently derived replicates.
For allele specificity, an RT-PCR scheme targeting exon 6 was employed to differentiate the two
alleles using the DelKO mutant, which contains a deletion in its exon 6 of Peg3 (Figure 3.5 A).
The tissues isolated from DelKO(+/-p) and DelKO(-m/+) were used to test the maternal and paternal
expression of the alternative transcripts, respectively (Figure 3.5 B). For tissue specificity, total
RNA was isolated from twelve individual tissues of adult mice, including the olfactory bulb
(OB), midbrain (MB), hypothalamus (HT), cerebellum (CB), thymus (TM), heart (HR), lung
(LG), liver (LV), kidney (KD), fat (FT), testis (TT), and ovary (OV). For stage specificity, total
RNA was also isolated from one-day-old neonatal brains (NB), and the results from these
neonatal brains were compared with those from the four different parts of the adult brains (OB,
MB, HT, CB). Two sets of total RNA from DelKO(+/-p) and DelKO(-m/+) were first reversetranscribed, normalized with the expression level of an internal control (β-actin), and finally used
for the expression analyses of the alternative transcripts.
The results from this series of expression analyses are summarized as follows. First, U3
transcript was detected at very low levels only in the hypothalamus (HT) and cerebellum (CB) of
the adult mice, but not in the neonatal brains (NB), indicating its specific expression in HT and
CB in the adult stage. This expression pattern was also independently confirmed through the
samples from wild-type mice, showing exclusive expression of U3 transcript in the mid-brain
and cerebellum (Figure 3.6 B). More importantly, U3 transcript was detected only in the tissues
of DelKO(+/-p), indicating maternal allele-specific expression. Second, U2 transcript appeared to
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be neonatal-specific, as expression was detected only in the two neonatal brain samples,
DelKO(+/-p) and DelKO(-m/+).

Figure 3.6. RT-PCR analysis of alternative exons in wild-type mouse tissues. (A) A schematic of
the mouse Peg3 locus with RT-PCR primer combinations. Gray and black boxes indicate the
exons of Usp29 and Peg3, respectively. Transcriptional direction for each gene is represented
using arrows with corresponding colors. The red arrows indicate the directionality of primers:
Ex6- R3 coupled with E1, U0, U1, U2, and U3 specific primers to amplify the respective exons.
(B) Allele, tissue, and stage-specificity of upstream alternative exons of Peg3. The RT-PCR
panel shows the expression patterns of Peg3 using total RNA isolated from tissues of wild-type
mice: OB (olfactory bulb), MB (midbrain), HT (hypothalamus), CB (cerebellum), TM (thymus),
HR (heart), LG (lung), LV (liver), KD (kidney), FT (fat), TT (testis), OV (ovary), NB (neonate
brain), MEF (mouse embryonic fibroblasts), E14.5 (Embryo14.5-dpc.), and PC14.5 (Placenta
14.5-dpc). U3-Ex6R3, U2-Ex6R3, and U1-Ex6R3 primer combinations target the upstream 1st
exons of Peg3; U0-Ex6R3 primer combination targets a shared upstream exon of Peg3, whereas
E1-Ex6R3 primer combination targets the main promoter of Peg3 to show the expression profile
preferred by each exon. The combination of exon 1 and exon 2 primers was used for the
expression pattern of Usp29. The β-actin expression profile serves as a control to visualize the
relative mRNA levels.
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This also indicated bi-allelic expression of U2 transcript although the expression levels from the
paternal allele were much higher than those from the maternal allele. Thus, the expression of U2
transcript is bi-allelic but with a bias toward the paternal allele. Independent analyses also
indicated that U2 transcript is not detectable in 14.5-dpc embryos and placentas, further
confirming its neonatal-specific expression (Figure 3.6 B). Third, the expression of U1 transcript
was detected in the hypothalamus (HT) and also in the ovary (OV). Interestingly, U1 transcript
was present in the hypothalamus (HT) of DelKO(+/-p), and absent from that of DelKO(-m/+), thus
indicating a maternal allele-specific expression pattern for U1, similar to U3 transcript. The
expression of U1 transcript in ovary (OV) was further investigated by performing an independent
RT-PCR and also 5’RACE experiments using mature oocytes. U1 transcript was not detected at
all in mature oocytes (data not shown), indicating that the observed expression of U1 transcript
likely originated from either the early-stage oocytes or the somatic cells of ovary. Fourth, a series
of RT-PCR surveying U0 exon detected the expression from the hypothalamus (HT), cerebellum
(CB), and ovary (OV) of DelKO(+/-p) and also from the neonatal brains (NB) of both DelKO(+/-p)
and DelKO(-m/+). This is reasonable since the three alternative transcripts, U1, U2, and U3, which
contain the U0 exon, were detected from the same tissues that show the U0 transcript.
Interestingly, the same RT-PCR also detected the expression from the testis (TT), which was not
detected by the previous RT-PCR surveying U1, U2, U3 transcripts. This suggests that additional
unknown transcripts may exist in testis. Multiple minor PCR products observed throughout this
expression analysis (U3, U2, U1 and U0) were confirmed to result from splicing variations
(Figure 3.5 B). Taken together, this series of expression analyses concluded that U1 and U3
transcripts are maternal allele-specific whereas U2 is bi-allelic with a bias toward the paternal
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allele. In addition, the main expression sites of these alternative transcripts include the
hypothalamus for U1 and U3 and the neonatal brain for U2.
DNA methylation analysis of the alternative promoters of Peg3
DNA methylation status of the three alternative promoters was further analyzed given
their allele and tissue-specific expression patterns. Genomic DNA was first isolated from four
different parts of the brain: olfactory bulb (OB), hypothalamus (HT), midbrain (MB), cerebellum
(CB), as well as kidney (KD) of a wild-type female adult mouse (Figure 3.7). The isolated DNA
was treated with the bisulfie conversion protocol [26], and the converted DNA was used as a
template for PCR amplification. Four different regions were targeted for DNA methylation
analyses: E1, U1, U2 and U3 promoter regions. The amplified PCR products were analyzed first
by COBRA (Combined Bisulfite Restriction Analysis [27]), and later by individual sequencing
(Table 3.3, Figure 3.7).
Table 3.3. Summary of the alternative promoter positions for DNA methylation analysis.
Upstream promoter/exon
(Chr: 7)

Position (NCBI37/mm9)
direction towards Peg3

Position used for DNA
methylation analysis

U3
U2
U1
U0
E1

5’ (~157 bp) – 6,846,590 3’
5’ (~ 79 bp ) – 6,709,554 3’
5’ (~178 bp) – 6,703,769 3’
5’ 6,699,550 – 6,699,412 3’
5’ (~164 bp) – 6,682,968 3’

5’ 6,846,749 – 6,846,565 3’
5’ 6,760,018 – 6,759,695 3’
5’ 6,704,151 – 6,703,900 3’
N/A
5’ 6,846,749 – 6,846,566 3’

The promoter region of an imprinted gene usually derives 50% methylation level due to
its allele-specific methylation status: one allele is methylated while the other allele is
unmethylated. The allele-specific methylation pattern is very uniform and complete among
individual CpG sites in a given promoter and also among individual tissues. This is the case for
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E1 promoter, which is part of the 4-kb Peg3-DMR, showing 50% methylation level among all
the tissues tested.

Figure 3.7. DNA methylation analysis of alternative promoters of Peg3. (A) DNA methylation
analysis of the E1, U1, U2, and U3 promoter regions. Genomic DNA was purified from the
different parts of the brain (olfactory bulb, hypothalamus, midbrain, cerebellum) and kidney of a
two-month-old female mouse, and then used for bisulfite conversion. The bisulfite-converted
DNAs were subsequently amplified with PCR using specific primer sets designed for each
promoter region (Table S1). The amplified PCR products were analyzed by COBRA. The
restriction enzymes used for each digestion is shown on the left side of the panel, while the right
side of the panel indicates the promoter regions under investigation. The red lines indicate
methylated DNA whereas the blue lines indicate unmethylated DNA. The methylation levels of
U2 and E1 promoter regions were calculated using the ImageJ software for three independent
trials. (B) Quantitative methylation analysis of U1 and U3 promoter regions. The bisulfiteconverted DNAs were amplified with PCR and used for NGS-based deep sequencing to obtain
the methylation level for each adult mouse tissue. A single red box and a blue box indicate a
single read for methylated and an unmethylated CpG site, respectively. Each column in the
methylation array represents a single CpG site for the respective tissue sample. The U3 and U1
promoter regions represent DNA methylation changes observed from four and six CpG sites,
respectively. The overall percentage of methylation is indicated at the bottom of each tissue for
comparison. The number of reads are represented by the (n) underneath each tissue sample.
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On the other hand, the methylation levels and patterns of the three alternative promoters are quite
different from those from E1. First, U1 promoter also showed around 50% methylation levels,
but the levels were variable among the tissues, ranging from 43% in the hypothalamus (HT) to
61% in the cerebellum (CB). Detailed inspection further indicated that the methylation level and
pattern of each CpG site were also variable compared to that of the remaining CpG sites. This is
quite different from the uniform and complete pattern observed from E1 promoter, thus
suggesting that the DNA methylation on U1 promoter may not be of allelic origin. The same
may be the case for U3 promoter, as its individual CpG sites displayed fluctuating levels of DNA
methylation. Compared to the U1 promoter, the overall methylation levels of U3 promoter were
greater, ranging from 68% in the hypothalamus (HT) to 82% in the olfactory bulb (OB) and
kidney (KD). This is somewhat consistent with the higher expression levels observed from U1
transcript than those from U3 transcript (Figure 3.5 B). Also, the methylation levels of both U1
and U3 promoters in the hypothalamus were the lowest among the tissues tested, which also
agrees with the fact that the expression of U1 and U3 transcripts were observed only from the
hypothalamus. Finally, U2 promoter displayed the greatest DNA methylation levels among the
alternative promoters, ranging from 85.4% in the cerebellum (CB) to 92.3% in the olfactory bulb
(OB). This is again consistent with the fact that the expression of U2 transcript was not
detectable at all in the adult tissues (Figure 3.5 B). Overall, this series of analyses concluded that
the methylation levels and patterns of the alternative promoters are variable among individual
tissues and also among individual CpG sites. Thus, the DNA methylation on the alternative
promoters is somewhat different from the typical pattern of allelic origin, although the
expression of U1, U2, and U3 transcripts appears to be biased in either the maternal or the

73

paternal allele. Nevertheless, this aspect of the results is inconclusive at the moment, which
requires further investigation in the near future.
Identification of the alternative 1st exon and promoter of human PEG3
The genomic structure of the Peg3 imprinted domain is well conserved among individual
mammals, including humans [2, 8]. Thus, we tested the presence of potential alternative 1st exons
and promoters of human PEG3. This test also used a similar strategy involving 5’RACE and
NGS sequencing as described above (Figure 3.8 A). The total RNA isolated from adult and
neonate brain tissues was first reverse-transcribed with a gene-specific primer targeting exon 2 of
human PEG3 (Ex2-R1), and later these cDNA fragments were further amplified with a set of
nested primers (Ex2-R2 and Ex2-R3). The two amplified libraries were sequenced using a NGS
platform. The results are summarized in Figure 3.8 B. According to the results, about 74% of the
sequence reads from the adult brain (255,571/342,369) belong to the known 1st exon of human
PEG3 (E1). On the other hand, 0.13% of the sequence reads (433/342,369) derived from a 120bp region that is located 2.4-kb upstream region of E1 exon. Yet, these sequences were not
connected to the E1 exon, but directly connected to the 2nd exon of PEG3 (E2). Also, this set of
cDNA sequences shows a similar pattern as seen from the three alternative promoters of mouse
Peg3, as a clear exon-intron border exists in their 3’-end sequences but not in their 5’-end
sequences. Therefore, this exon is predicted to be an alternative 1st exon of human PEG3, thus
named U1. Interestingly, this U1 exon was not detected in the library derived from the neonate
brain, thus indicating an adult-specific expression (Figure 3.8 B). To further confirm this
possibility, we also performed a set of RT-PCR testing the expression pattern of U1 exon (Figure
3.8 C). As expected, the expression levels of the human PEG3 transcript starting from E1 exon
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were very high in both adult and neonatal brains (AB and NB), and also in the other adult tissues,
including heart (HR), liver (LV), kidney (KD) and placenta (PC).

Figure 3.8. Upstream alternative promoter of human PEG3. (A) A schematic of the human PEG3
locus with RT-PCR primer combinations. Gray and black boxes indicate the exons of MIMT1
and PEG3, respectively. Transcriptional direction for each gene is represented using arrows with
corresponding colors. The black arrow indicates the directionality of Ex2-R1, the primer used for
cDNA synthesis. The open oval represents the alternative 1st exon U1. (B) 5’ RACE analysis for
upstream exons of PEG3. The Ex2-R2 indicates the anchoring primer used for nested PCR after
5’ RACE. This primer was coupled with U1 and E1 specific primers to amplify the respective
exons. The percentage of transcripts preferred by the adult human brain was calculated by
counting the sequences specific for U1 and E1. (C) RT-PCR analysis of upstream alternative
exons in human tissues. The RT-PCR panel shows the expression patterns of PEG3 using cDNA
from AB (adult brain), NB (neonate brain), HT (adult heart), LV (adult liver), KD (adult kidney)
and PC (adult placenta). U1-Ex2R2 and E1-Ex2R2 primer combinations amplified the upstream
exons of PEG3 to show the expression profile preferred by each 1st exon. The Ex1-Ex2 primer
combination amplified the expression pattern of MIMT1 in the AB and NB. Equal amounts of
total RNA were used for RT-PCR, which were normalized by β-actin expression levels.
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On the other hand, the expression of the human PEG3 transcript starting from U1 was detected at
very low levels only from the adult brain (AB) and placenta (PC). This low level of expression in
adult brain agrees with the initial detection of this exon from the library that had been derived
from adult brain. Also, this appears to be somewhat similar to the mouse U1 and U3 transcripts
since they are also expressed only in the adult stage. Overall, this series of 5’RACE and
expression analyses confirmed that human PEG3 also harbors an alternative 1st exon and
promoter. Thus, alternative 1st exons and promoters may be evolutionarily conserved features
that are associated with the mammalian Peg3 domain.

3.4 Discussion
In the current study, we have identified three alternative promoters for mouse Peg3 and
one alternative promoter for human PEG3. These alternative promoters are localized within the
200-kb upstream regions of mouse and human PEG3, which are well conserved among
mammals in terms of genomic structure. In mouse, two of these promoters, U1 and U3, derive
maternal-specific expression whereas the remaining promoter, U2, derives bi-allelic expression
of Peg3 with a paternal allele bias. These promoters are also tissue and stage-specific: U1 and
U3 transcripts are detected in the hypothalamus of adult mice whereas U2 transcript only in
neonatal-stage brains. In humans, U1 transcript is detected at relatively very low levels in adult
brain and placenta. Overall, the identification of alternative promoters in both mouse and human
suggest that these alternative promoters may be functionally selected features for the Peg3
imprinted domain during mammalian evolution.
The current study has identified alternative promoters for human and mouse PEG3 with a
strategy involving 5’RACE and NGS-based deep sequencing experiments (Figure 3.2, Figure
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3.8). The identified alternative promoters are all located within the 200-kb genomic interval that
is upstream of the Peg3 locus (Figure 3.9).

Figure 3.9. Evolutionary conservation of mammalian Peg3 domains. The 500-kb genomic
interval of the Peg3 imprinted domain is represented using the mouse region as a representative
locus. The blue and red colors indicate paternally expressed (APeg3, Peg3, Usp29, Zfp264) and
maternally expressed genes (Zim1, Zim2, Zim3), respectively. Transcriptional direction for each
gene is represented using arrows with corresponding colors. The evolutionarily conserved
regions (ECRs) are shown using green lines. The upstream alternative promoters for Peg3 in
mouse chromosome 7 are shown using three black arrows. The upstream alternative promoter for
PEG3 in human chromosome 19 is shown using a black arrow. The dotted box indicates the
genomic region responsible for stillbirth in cows (64,325,122-64,431,506). The evolutionary
conservation of the mammalian Peg3 domains is indicated by the mammal conservation plot,
which is represented in green.
This 200-kb genomic interval has been well conserved during mammalian evolution although
this region lacks an obvious ORF [8]. According to recent studies, this genomic interval contains
18 evolutionarily conserved regions (ECRs), and these ECRs are all associated with H3K4me1
and/or H3K27ac [9]. Thus, these ECRs are thought to be potential enhancers. Some of the
alternative promoters are in fact closely associated with these ECRs. For instance, U2 is
localized between ECR3 and ECR4, whereas U3 is located nearby ECR18. This may be an
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indication that some of the ECRs are enhancers for these alternative promoters. On the other
hand, a similar series of inspection was unable to confirm the association of any histone marks,
such as H3K4me3, with these alternative promoters, which might be caused by their very low
abundance. Recent studies from the bovine genome also revealed that a deletion of a 20-kb
genomic interval encompassing U2 promoter might be responsible for the stillbirths observed
among the calves that had been derived through artificial insemination [28]. This observation is
intriguing in that U2 promoter is very specific in neonatal-stage brains (Figure 3.5). This further
suggests that these alternative promoters may play very unique, but critical roles for the
transcription control of Peg3. Overall, the identification of alternative promoters in mouse and
human PEG3 appears to provide an answer for a long-standing, puzzling question: why is the
middle 200-kb genomic region of the Peg3 domain preserved so well during mammalian
evolution? This region most likely harbors several cis-regulatory elements critical for the Peg3
domain, and one set of these should be the newly identified alternative promoters for human and
mouse PEG3.
The three alternative promoters of mouse Peg3 are quite interesting in terms of their
expression patterns (Figure 3.5). First, one of the main expression sites shared among the three
promoters is the hypothalamus. It is well known that Peg3 is highly expressed in the
hypothalamus [1, 3, 10, 22], and the in vivo functions of Peg3 are closely associated with several
roles played by this part of brain, such as milk provision and maternal-caring behavior [10]. The
similar expression pattern shared between the new alternative promoters (U1, U3) and the known
major promoter (E1) suggests that U1 and U3-driven transcripts likely play similar roles as the
main transcript by E1 promoter. This further suggests that unknown cis-regulatory elements may
exist for this hypothalamus-specific expression of these promoters. Second, U2 promoter shows
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a highly sensitive, stage-specific expression, showing its expression exclusively in one-day-old
neonates, but not in 14.5-dpc embryos or adult tissues (Figure 3.6). Thus, this promoter might be
functional only during a particular stage when neonates’ brain is known to undergo a series of
major organization processes, especially in the hypothalamus region [29, 30]. Therefore, the
main roles of this promoter might be associated with many changes occurring during this
transition period of brain development. Third, two of the alternative promoters, U1 and U3, show
maternal allele-specific expression patterns. It is puzzling at the moment why these alternative
promoters derive maternal-specific expression for the paternally expressed Peg3 in the
hypothalamus. One possible explanation would be that some of cell populations within the
hypothalamus might require additional dosage of Peg3. As a consequence, Peg3 might be biallelic in those cell populations: maternal by U1 and U3 and paternal by E1 promoter. Since the
alternative promoters reside within the paternally expressed Usp29 transcriptional region,
transcriptional interference by Usp29 could be another possible explanation for the allelespecific expression patterns observed by U1, U2 and U3 [31]. In spite of the observed allelespecific expression, however, DNA methylation pattern suggests that it is unlikely of allelic
origin (Figure 3.7). Nevertheless, the absence of sequence polymorphisms in the alternative
promoter regions between different subspecies of the mouse hampered the inquiry of allelespecific DNA methylation. Overall, the newly identified alternative promoters exhibit very
interesting expression profiles, which have not been observed before. Thus, characterizing these
promoters should provide additional insights regarding the in vivo function of Peg3.
Alternative promoters have also been identified from other imprinted domains, such as
Grb10, Snrpn/Ube3a, Gnas and Zac1 domains. Interestingly, the two alternative promoters for a
given locus tend to be opposite in terms of their allele-specific expression. The examples include
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maternal and paternal-specific promoters in Grb10 and Gnas [15-17, 20]. Because of the current
study, this list includes the maternal and paternal-specific promoters for the Peg3 locus as well.
According to the observations from other domains, several in vivo roles are possible for the
alternative promoters of the Peg3 locus. First, the two promoters for Grb10 have two
complementary expression patterns. The paternal and maternal promoters of Grb10 are
responsible for its expression in neuronal and non-neuronal cells, respectively [32]. Thus, this
might be feasible for the alternative promoters for Peg3: the paternal and maternal promoters
could function in different population of cells within the hypothalamus. Second, one upstream
alternative promoter for the Snrpn locus is also involved in regulating the allele-specific
expression of the nearby gene, Ube3a, which is located 500-kb downstream of Snrpn. This
particular promoter derives the paternal-specific transcription of a long non-coding Ube3a-ATS
[12]. Furthermore, this antisense transcript is thought to be responsible for maintaining the
maternal-specific expression of Ube3a [13, 14]. The alternative promoters of Peg3 might also
play similar roles. In particular, U3 promoter is located 160-kb upstream of Peg3, yet the
transcription initiated from this promoter extends all the way downstream to the Peg3 locus. It is
possible that the transcription starting from U3, particularly from the maternal allele, might be
related to the expression of two maternally expressed downstream genes of Peg3, Zim1 and
Zim2. Besides these two possible roles, the alternative promoters might be also involved in the
DNA methylation setting for the Peg3-DMR during oogenesis. A similar situation is known to
occur in the Gnas, Snrpn, and Zac1 loci [13, 14, 17, 19]. According to a deep transcriptome
sequencing study of the mouse oocytes, several alternative promoters were identified for
individual imprinted genes including Peg3 [19]. However, none of the three alternative
promoters of the Peg3 locus seem to be functional and thus detectable in mature oocytes, based
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on our preliminary results obtained so far (data not shown). Thus, these promoters might not play
a similar role in DNA methylation setting as seen in these loci. Overall, the information from the
other imprinted domains appears to provide several hints regarding the potential roles that might
be played by the alternative promoters of Peg3. Thus, it should be very interesting to pursue
these aspects of the identified alternative promoters in the near future.
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CHAPTER 4
NGS-BASED 5’RACE FOR ALTERNATIVE PROMOTERS 3

4.1 Introduction
In eukaryotic cells, gene transcription is regulated through several cis-regulatory DNA
elements, such as promoters, enhancers, silencers and insulators [1]. Identifying promoters is one
of the initial steps for characterizing transcriptional regulation for any given gene. In model
organisms, the promoters of the majority of genes have been identified through large-scale
sequencing efforts [2]. According to recent results, however, transcripts are quite often detected
from the upstream regions of many genes that are outside of the previously defined transcribed
regions. This indicates that additional transcription start sites and alternative promoters may exist
for many genes [3]. In the current study, thus, we have modified and adapted the existing
5’RACE (Rapid Amplification of cDNA Ends, [4]) approach into an NGS (Next Generation
Sequencing)-based new protocol that can identify the alternative promoters for these transcripts.
The main strength of this new protocol is its sensitivity: this can detect the 5’-ends of mRNA that
are of very low abundance. The main ideas and detailed steps for this protocol are described
below.
Two main ideas have been incorporated into this new protocol. First, the initial cDNA for
5’RACE needs to be prepared with the reverse transcription reaction using gene-specific
oligonucleotide primers (Figure 4.1 B). These gene-specific primers also need to be derived from
the known 2nd exons, but not from the known 1st exons for genes. The known 1st exons are not a
good choice since these 1st exons do not have splicing acceptor sites at their 5’ ends. Instead,
3

This chapter previously appeared as: Perera, B. P. U., and Kim, J. (2016) Next-generation
sequencing-based 5’ rapid amplification of cDNA ends under Analytical Biochemistry 494: p.
82-4. Modified and reprinted with permission from Elsevier.
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they have transcription start sites, thus they cannot be connected to any upstream exons.

Figure 4.1. Overall scheme for the NGS-based 5’RACE protocol. (A) A flow chart shows the
entire procedure of the NGS-based 5’RACE protocol. (B) A schematic illustration represents the
genomic structure of a given locus with its promoters and exons being indicated by triangles and
rectangles, respectively. The bent arrow indicates the transcriptional direction of the gene. The
previously known transcript and its alternative transcript are shown in black and light blue,
respectively. The total RNA isolated from the desired tissue is first reverse-transcribed using
gene-specific primers, as indicated by the black arrow underneath the exon structure. The
resulting cDNA product is then purified and modified with the tailing reaction using dGTP and
TdT, as indicated by the extended blue and black arrows with a ‘G’ mark. The cDNA is then
used as a template for a nested PCR scheme I with the following two primers: an internal genespecific primer (gray arrow) and a primer made of a unique sequence plus a C-tail (indicated by
XC). The product from PCR I is subsequently used for PCR II with another internal genespecific primer (gray arrow) and the second primer specific for the unique sequence (arrow
indicated by X). The resulting products are end-repaired and ligated to barcoded adapters as
shown by the green boxes. A set of several 5’RACE libraries can be pooled together for NGSbased sequencing. The sequences from NGS runs are sorted based on the barcoded adapters and
also the G-tailed and gene-specific primer portion of the cDNA products. These sorted sequences
are further divided into individual groups based on their different combinations of exon joining.
These groups of the sorted sequences are analyzed to examine their exon structures using the
UCSC genome browser. Each group with a different exon joining can also be analyzed for the
frequency (or representation) in a given library.
By contrast, the known 2nd exons have proper splicing acceptor sites, thus should be ideal
regions anchoring the upstream alternative exons that have not been identified so far. Second,
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potential unknown alternative 1st exons most likely represent the sequences that belong to very
low abundant transcripts, given all the sequencing efforts by the genomic community. Therefore,
this new protocol utilizes NGS-based approaches to identify the sequences derived from these
very minor transcripts. NGS-based sequencing should allow the identification of these low
abundant transcripts given their sequencing capacity, million reads per library. This new
protocol, therefore, includes several steps that can easily convert PCR products into NGS
libraries.

4.2 Materials and Methods
The detailed steps for the new protocol are as follows (Figure 4.1 A). In Step 1, the total
RNA isolated from tissues samples is reverse-transcribed with gene-specific primers (dark arrow
in Figure 4.1 B). The subsequent cDNA needs to be purified through phenol/chloroform
extraction followed by ethanol precipitation. In Step 2, the cDNA is modified through the tailing
reaction using dGTP and terminal deoxynucleotidyl transferase. In Step 3, a pool of the G-tailed
cDNA is targeted and enriched for a given gene through a nested PCR scheme involving two sets
of primers: two gene-specific primers (gray arrows) and two primers targeting the G-tailed
portion of cDNA (XC and X; blue arrows). A small amount of PCR products from each PCR
needs to be separated on a 2% agarose gel to monitor the proper amplification of cDNA. In Step
4, the amplified product from the 2nd PCR is modified with the end-repair reaction, and later with
the ligation reaction to be analyzed with NGS sequencing. The current protocol has been tested
multiple times using a NGS platform (PGM2, Ion Torrent), which requires two specific
sequences at either end of all the DNA fragments to be analyzed (A and P adaptors). Thus, the
two adaptors containing these sequences need to be ligated onto either end of the cDNA. An
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NGS platform usually allows the simultaneous sequencing of multiple libraries, thus several
cDNA libraries derived from multiple tissues are also ligated individually with a set of adaptors
with different barcodes. In Step 5, the pool of individual barcoded libraries is amplified with
PCR, and subsequently sequenced using a NGS platform. In Step 6, the raw sequence reads from
NGS runs are sorted first by their barcodes, and later by the sequences of the two primers: X and
the gene-specific primer used for the 2nd PCR of the nested scheme (Figure 4.1 B). This sorting
process can be executed through several Unix command lines, which has been included below.
These filtered reads are further processed to identify alternative exons using a PERL script,
which can detect and count the number of the raw reads that have different combinations of exon
joining with the initial exon (E2 in Figure 4.1 B). In Step 7, each group of the raw reads
displaying different exon joining can be mapped to the genome sequence of a given species
using the UCSC genome browser, which will then identify new alternative exons.
Reagents
A Adapter with barcode:
5’-CCATCTCATCCCTGCGTGTCTCCGACTCAGXXXXXXXXXXGAT-3’

(X,

10mer

barcode)
A adaptor primer: 5’-CCATCTCATCCCTGCGTGTC-3’
Bst2.0 WarmStart DNA polymerase (includes 10X Isothermal Amplification Buffer; New
England Biolabs. Cat. No. M0538S)
DNA Clean & ConcentratorTM-25 (includes spin columns, DNA Binding Buffer, Wash Buffer,
Elution Buffer, Zymo, Cat. No. D4005)
Gene-specific primers for the gene of interest
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NEBNext End Repair Module (includes NEBNext End Repair Enzyme Mix, NEBNext End
Repair Reaction Buffer; New England Biolabs, Cat. No. E6050S)
P1 Adaptor:
5’-CCACTACGCCTCCGCTTTCCTCTCTATGGGCAGTCGGTGAT-3’
P1 Adapter Primer: 5’-CCACTACGCCTCCGCTTTCC-3’
Phenol/Chloroform from Sigma (cat: P2069-200ML)
Reverse transcription reagents from New England Biolabs (NEB)
T4 DNA Ligase (includes 10X T4 DNA Ligase Reaction Buffer; New England Biolabs, Cat. No.
M0202S)
XC primer: 5’-GGTTGTGAGCTCTTCTAGATCCCCCCCCCCCCNN-3’
X primer: 5’-GGTTGTGAGCTCTTCTAGA-3’
TE buffer (1X, pH 8.0)
Terminal Transferase from NEB (cat: M0315S)
Trizol reagent from Life Technologies (cat: 15596-018)
Zymoclean Gel DNA Recovery Kit (includes spin columns, ADB Buffer, Wash Buffer, Elution
Buffer; Zymo, Cat. No. D4001)
Equipment
2100 Agilent Bioanalyzer System
Agarose gel (2%) and equipment for electrophoresis
Centrifuge (Benchtop centrifuge for 1.5ml microcentrifuge tubes)
E-Gel Precast Agarose Electrophoresis System
Ion torrent PGM NGS machine
Thermocycler
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cDNA synthesis and purification
1. Isolate RNA from the tissue of interest using Trizol reagent according to the
manufacturer’s protocol. Use equal amounts of RNA to synthesize cDNA using gene
specific primers.
2. Prepare the cDNA synthesis reaction as shown below.
Component

Volume

Total RNA (5µg)

Xµl

dNTP (2.5mM)

8µl

Gene-specific primer (10µM)

2µl

H2 O

Yµl

Total

32µl

3. Incubate at 65oC for 5 mins in the thermocycler.
4. Prepare the following items to complete the reverse transcription.
Component

Volume

Template from (3)

32µl

5X RT buffer

8µl

RNase Inhibitor (10U/µL)

2µl

DTT (0.1M)

4µl

M-MuLV RT enzyme (200u/µL) 2µl
Total

48µl
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5. Incubate at 42oC for 1 hour for reverse transcription and 90oC for 10 mins to inactivate
the enzyme with the thermocycler.
6. Mix the cDNA with an equal amount of 1X TE. Monitor the cDNA quality with PCR
using gene specific primers. Check the amplified PCR products through a 2% agarose
gel electrophoresis at 100V for 30 mins.
Cycle number

Denature

1

95oC, 2min

33

95oC, 30s

Anneal

Extension

60oC, 30s

72oC, 60s
72oC, 7min

1

7. Perform phenol/chloroform extraction. First, bring the cDNA volume up to total 200µl
with 1X TE. Add 100µl of phenol/chloroform, vortex, and centrifuge at 13,000 rpm for 6
mins. Save the top 150µl aqueous solution for the next step.
8. Precipitate the cDNA with 100% ethanol at -20oC for 1 hour as described below.
Component

Volume

cDNA template (7)

150µl

Sodium Acetate

15µl

Glycogen

3µl

100% Ethanol

300µl

Total

468µl

9. Centrifuge the cDNA solution at 13,000 rpm for 15 mins at 4oC, and pipet the
supernatant out of the tube.
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10. Add 1mL of 70% ethanol, centrifuge the sample(s) at 13,000 rpm for 10 mins at 4oC, and
pipet out the supernatant. Air-dry the pellet for 10 mins until the ethanol is evaporated
completely.
11. Resuspend the pellet with 37µl of H2O. This can be stored at -20oC for a few days.
Tailing reaction and nested PCR procedure
12. Prepare the following items to complete the tailing reaction.
Component

Volume

Purified cDNA template (11)

37µl

Cobalt Chloride (2.5mM)

5µl

dGTP (1mM)

2.5µl

TdT buffer (10x)

5µl

TdT enzyme

0.5µl

Total

50µl

13. Incubate at 37oC for 30 mins and later 70oC for 10 mins to stop the reaction using the
thermocycler.
14. For the nested PCR 1, use 1µl of the G-tailed cDNA fragments with the XC primer (5’GGTTGTGAGCTCTTCTAGATCCCCCCCCCCCCNN-3’)

and

an

internal

gene-

specific primer to amplify the desired transcript. Monitor the amplified products with a
2% agarose gel electrophoresis at 100V for 30 mins. This same PCR amplification
conditions were applied as step 6 (this reaction employed 36 cycles).
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15. For the nested PCR 2, use 1µl of the nested PCR 1 product with the X primer (5’GGTTGTGAGCTCTTCTAGA-3’) and another internal gene-specific primer to amplify
the desired transcript. Monitor the PCR products on a 2% agarose gel electrophoresis.
Cycle number

Denature

1

95oC, 2min

25

95oC, 30s

Anneal

Extension

60oC, 30s

72oC, 60s
72oC, 7min

1

Prepare the libraries for NGS
16. Prepare the end repair reaction as described below.
Component

Volume

PCR product (15)

Xµl

End repair enzyme mix

5µl

End repair reaction buffer (10X)

10µl

H2 O

Yµl

Total

100µl

17. Incubate at 20oC for 30 mins in a thermocycler
18. Prepare a 2% agarose gel for size selection.
19. Load the entire DNA sample into one or two wells along with a 100-bp size marker in a
separate well, and run the gel at 130V for 40 mins.
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20. Excise a section of the agarose gel containing the PCR products with the desired size
range (<400bp length), and extract the DNA from the gel using Zymoclean Gel DNA
Recovery Kit. Finally, elute the DNA in 20µl of the elution buffer.
21. Prepare the adapter ligation reaction as described below.
Component

Volume

Size selection sample

17µl

Bst2.0 warm polymerase (8000 U/ml)

1µl

Bst2.0 polymerase buffer (10X)

4µl

T4 DNA ligase (400,000 U/ml)

4µl

T4 DNA ligase buffer (10X)

4µl

P1+A Barcode Adapter (10 pmole/ul)

10µl

Total

40µl

22. Incubate the sample at 25oC for 25 mins, 65oC for 30 mins, and finally 80oC for 20 mins
to stop the reaction.
23. Repeat the size selection step as described above (20-21) to exclude any adapter dimers.
Elute the DNA sample in 6µl of H2O.
24. Perform PCR to amplify the eluted DNA with a set of the two primers corresponding to P
and A1 adapter: P1 adapter primer, 5’-CCACTACGCCTCCGCTTTCCTCT-3’; A
adapter primer, 5’-CCATCTCATCCCTGCGTGTCTCC-3’.
25. The detailed program for PCR is shown below. The typical number of PCR cycles
ranges from 10 to 14.
Cycle number

Denature

1

95oC, 5min

Anneal

Extension
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10 – 14

95oC, 30s

68oC, 30s

72oC, 45s
72oC, 10min

1

26. Clean up the final PCR product with DNA Clean & Concentrator Kit.
27. Size-select the amplified library with E-Gel Precast Agarose Electrophoresis system.
28. Clean up the selected DNA library with DNA Clean & Concentrator Kit.
29. Perform NGS-based sequencing with the prepared library.
Bioinformatics process
The raw sequences with the different barcodes are first sorted and provided as individual fastq
files from NGS platform. These fastq files are processed in the following manner to identify
alternative exons and promoters.
1. Count the number of the cDNA sequences that contain the sequences of both the G-tailed
portion and the 2nd nested gene-specific primer portion with the following command line
(grep –E ‘X part of the G-tailed primer sequence’ ‘the name of fastq file’ | grep –E ‘the
sequence of the 2nd nested primer’ | wc -l). Once the number of the cDNA sequences is
reasonable (at least greater than 0), then retrieve the sequences with the following
command line (grep –E ‘X part of the G-tailed primer sequence’ ‘the name of fastq file’ |
grep –E ‘the sequence of the 2nd nested primer’ > ‘the name of the sorted file with the
forward orientation’). These processes need to be repeated with a set of complementary
sequences to retrieve the sequence reads with the reverse direction.
2. Count and group the sequences in the sorted file in the forward orientation based on their
different combinations of exon joining using a Perl script with the following command
line (perl test_RP_counter.pl ‘the name of the sorted file with the forward orientation’
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‘the sequence of the 2nd nested primer’). The execution of this command line generates
the number of the sequences containing each of the 16 different combinations of
randomized 2 bp sequences (4x4) right after the sequence of the 2nd nested primer, which
is designed to be located at the 3’-end of the known 2nd exon. This process also needs to
be repeated with the opposite orientation (perl test_RP_counter.pl ‘the name of the
sorted file with the reverse orientation’ ‘the complementary sequence of the 2nd nested
primer’). This process will provide the information regarding how many sequences
contain different exon joining and how many different groups of exon joining are present
in a sequenced library.
3. Group the sequences based on the identified different combinations of exon joining. This
can be executed with the following command line (grep –E ‘the sequence of the 2nd
nested primer plus two additional bases’ ‘the name of the sorted file with the forward
orientation’ > ‘the name of the groups with different exon joining’). This needs to be
repeated again with the sequences with the opposite orientation.
Map the representative individual sequences from each group to the genome sequence of a given
species using the BLAT search in the UCSC genome browser. This mapping process will first
compare the exon structure of each group against the known exon structure of a given gene,
which will eventually identify its new alternative exons and promoters.

4.3 Results
The feasibility of this protocol has been tested through identifying alternative promoters
for an imprinted gene called PEG3 (Paternally expressed gene 3) (Figure 4.2). This gene is
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comprised of 9 exons that are spread throughout 25-kb genomic regions in both human and
mouse, and is highly expressed in the brain [5-7].

Figure 4.2. Alternative transcripts and promoters identified for mouse and human PEG3. (A) The
genomic structure of PEG3. The black and blue boxes represent the 9 previously known exons
and the newly identified alternative exons of PEG3, respectively. The bent black arrow indicates
the transcriptional direction of PEG3. The E1-E2 transcript contains the known 1st and 2nd exons
of PEG3. The mouse U1-E2 transcript harbors the newly identified alternative 1st exon, but skips
the known 1st exon of Peg3. The human U1-E2 transcript starts from the newly identified
alternative 1st exon, which also skips the known 1st exon of PEG3. (B) The relative frequency of
alternative transcripts for mouse and human PEG3. The table summarizes the relative
representation (%) of the transcripts with E1 (the known 1st exons) and U1 (alternative 1st exons)
of PEG3. The relative representations (%) are calculated through dividing the number of the
reads containing the E1, mU1 (mouse), and hU1 (human) exons by the total number of the reads
for each library. The total number of reads for each library represents the sorted sequences that
still contain both the G-tail and gene-specific primer portions at their 5’ and 3’-ends. (C) RTPCR analyses for alternative exons. The E1-E2 primer combination targets the transcript
containing the known 1st and 2nd exons of PEG3. The U1-E2 primer combination detects the
transcript with the newly found alternative 1st exon connected to the 2nd exon of PEG3. The top
and bottom panels represent the RT-PCR products from mouse and human brains, respectively.
Interestingly, the 200-kb upstream region of this gene is well conserved among all the mammals
without any additional ORFs (Open Reading Frames), thus this region has been suspected to
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harbor other unknown cis-regulatory elements [8]. This new protocol, therefore, has been applied
to test whether this region contains any unknown alternative promoters. First, the total RNA
from mouse and human brains were individually used for generating 5’RACE cDNA libraries,
and later these libraries were sequenced using a NGS platform. Each library derived on average
several hundred thousand reads, and these raw reads were further analyzed with the
bioinformatics strategy described previously. According to the results, the majority of cDNA
sequences were indeed derived from the transcripts with the known exon combination (E1-E2):
93% for mouse and 74% for human PEG3 (Figure 4.2 B). However, this protocol also detected
some minor transcripts from both mouse and human, and these transcripts were very low in
abundance, based on their representations in the libraries: 0.33% for mouse and 0.13% for
human PEG3. Detailed inspection further revealed that these minor transcripts skip the known 1st
exons but are connected to previously unknown alternative exons (U1 in Figure 4.2 A). It also
revealed that the new U1 exons of PEG3 are not conserved between mouse and human genomic
regions. Individual RT-PCR analyses indeed confirmed the presence of these minor transcripts
for mouse and human PEG3 (Figure 4.2 C). Until now, there has never been any clue suggesting
the presence of alternative promoters for the PEG3 locus, although this locus has been
intensively studied for more than two decades. Thus, this new protocol appears to be very robust
in identifying low abundant transcripts and corresponding alternative promoters.

4.4 Discussion
This newly developed protocol, NGS-based 5’RACE, may be used for other similar
studies that intend to identify low abundant transcripts for their gene of interest based on the
following reasons. First, this protocol is very sensitive: it can detect very low abundant
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transcripts and corresponding alternative promoters. As demonstrated above, this protocol
successfully detected a minor transcript that makes up only 0.1% of all transcripts from human
PEG3. This level of sensitivity cannot be achieved with the existing 5’RACE protocols. This
protocol also provides clear exon structures for a given locus, which is not always feasible with
other NGS data, such as RNA-seq, due to their relatively short read lengths. Second, the new
protocol can estimate the relative expression levels of the alternative transcripts for a given locus
among various tissues or stages. The number of raw sequence reads belonging to each transcript
can be easily converted into its relative representation in a given cDNA library, which can
further indicate the strength of the corresponding alternative promoter. This type of information
could be very important since the in vivo function of a given gene often manifests through its
tissue and stage-specific alternative promoters. Third, this protocol is reliable and reproducible.
We have tested more than 15 rounds of 5’RACE followed by NGS runs, and each round has
been consistently successful for identifying new alternative exons and promoters. Despite these
strengths, however, the current protocol also has one caveat. We have been selecting DNA
fragments less than 400 bp in length for actual NGS runs due to the read length limitation that
can be afforded by current NGS platforms. Thus, any 5’RACE cDNA products greater than 400
bp in length cannot be sequenced through the current protocol. Nevertheless, this NGS-based
5’RACE protocol appears to be a very sensitive and reliable method in identifying low abundant
alternative transcripts and promoters.
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CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS
Genomic imprinting plays critical functional roles in regulating fetal growth and
development along with neurological processes such as maternal behavior [1, 2]. This is seen
from a gene cluster found in the Peg3 imprinted domain, exclusively expressed in placental
mammals [3-5]. These genes are unevenly distributed in the ends of the 500-kb domain, leaving
a 250-kb conserved region that contains multiple ECRs that are most likely involved in
controlling the Peg3 domain via cis-regulatory mechanisms [6, 7]. The ICR of this region is
located at a DMR that corresponds to a bidirectional promoter of Peg3 and Usp29 [8]. This
region also contains several YY1 binding sites that suggest the involvement of trans acting
factors for imprinting regulation [9-11]. Therefore, it is safe to state that these cis- and transacting factors are important for imprinting and transcription of the Peg3 domain. This
dissertation presents data indicating how dosage of Yy1 is involved in controlling the Peg3
imprinted domain in vivo, and the discovery of alternative promoters that give rise to the Peg3
expression originating from its maternal allele in the brain.
Recently, reduced levels of YY1 using in vitro and in vivo RNA interference (RNAi)
mediated YY1 knockdown models led to an up-regulation of Peg3 expression and altered DNA
methylation levels throughout the Peg3 domain, suggesting that it may be a major trans factor
that regulates transcription and imprinting [11-14]. However, the in vivo function of YY1 is not
well understood. The next step is to understand how YY1 is involved in controlling the Peg3
domain in a dosage dependent manner. Here, we examined the in vivo effects of Yy1 gene dosage
on the Peg3 imprinted domain with various breeding schemes utilizing two sets of mouse mutant
alleles. The results indicated that half dosage of Yy1 coincides with the up-regulation of Peg3
and Zim1, suggesting that Yy1 acts as a repressor in the Peg3 imprinted domain. This study also
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led to an unexpected observation that the maternal allele of Peg3 is expressed in the adult mouse
brain, despite the fact that Peg3 is maternally imprinted and silent in other tissues. The
expression of Peg3 was found to be bi-allelic in the specific areas of the brain, including the
choroid plexus, the PVN and the SON of the adult mouse hypothalamus. This finding is quite
significant, as the hypothalamus region of the brain produces the needed hormones to control
caring behavior and development [2, 15]. PEG3 protein immunoreactivity was detected in the
hypothalamus, along with its enrichment in neurons involved in synthesizing the hormones
oxytocin and vasopressin, which play critical roles in labor, milk production and sexual behavior
[16]. Although the exact roles of the maternal allele expression of Peg3 in these cell types are
currently unknown, this new finding suggests that the maternal allele may be functional in
specific cell types. Moreover, it provides insight regarding the previously unnoticed bi-allelic
expression of Peg3 in the mouse brain. Overall, these results confirm the repressor role of Yy1 in
the Peg3 domain and also provide a new insight regarding the bi-allelic expression of Peg3 in
mouse brain. However, the mechanism underlying the maternal-allele expression patterns
observed in mouse brain remains to be elucidated.
The observed bi-allelic expression pattern may be a result of either de-repression of the
maternal allele of the known promoter or the presence of alternative promoters for the Peg3
locus. To explore this mechanism, we sought to identify the possibility of alternative promoters
responsible for its transcription and gene expression patterns using a method that employs NGSbased 5’RACE. As a consequence, in chapter three we identified three alternative promoters for
mouse Peg3 and one alternative promoter for human PEG3 upstream of their major promoter. In
the mouse, two of these alternative promoters drive maternal-specific expression of Peg3
specifically in the hypothalamus of the adult brain, while the third promoter drives bi-allelic
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expression of Peg3 with a paternal bias only in the neonatal-stage brain. In humans, an
alternative transcript is also detected at relatively very low levels in the adult brain and placenta.
These results reveal that alternative promoters display allele-, tissue-, and developmental stagespecific Peg3 expression patterns. This is a novel discovery, as most functional studies on Peg3
assume that the maternal allele is completely silent, and that a paternal transmission of a
knockout mutant is consequently devoid of all Peg3 expression. Therefore, many of the
behavioral and functional studies of Peg3 thus far may need to be carefully re-evaluated. These
alternative promoters are localized within the 200-kb upstream region of Peg3, in between
ECRs, suggesting that some enhancer-like elements have the potential to act as promoters as well
[17]. The identification of alternative promoters in both mouse and human models suggests that
these alternative promoters may be functionally selected features for the Peg3 imprinted domain
during mammalian evolution. Together, these findings contribute to the overall understanding of
the imprinting and transcription of Peg3 that was not reported during the past two decades of
research.
We modified the existing 5’RACE approach into an NGS-based new protocol in order to
identify alternative promoters for Peg3. In this work, we present a new method for detecting
alternative promoters that incorporates 5’RACE starting from the known 2nd exons of genes and
NGS-based sequencing of the subsequent cDNA products. This method can successfully detect
levels of mRNA that comprise less than 1% of total transcripts from a given gene, which to date
could not be achieved with existing 5’RACE techniques. Moreover, the relative expression levels
of the alternative transcripts can be estimated as an indicator of the alternative promoter
strengths. This protocol also provides clear exon structures for a given locus, which is not always
feasible with other NGS methods, such as RNA-seq, due to their relatively short read lengths.
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Finally, we provide a new method to identify alternative promoters using an NGS-based
5’RACE techniques, which was instrumental in the maternal allele-specific alternative promoters
responsible for the bi-allelic expression of Peg3. Overall, these results indicate that this NGSbased 5’RACE protocol is a sensitive and reliable method for detecting low-abundant transcripts
and promoters.
Based on the findings presented here, it would be of interest to further explore the
mechanistic and functional significance of these alternative promoters in vivo. For instance,
exploring the behavior of these alternative promoters in the absence of its major promoter would
provide more information about the transcriptional regulation of the alternative promoters. This
could be observed by utilizing various breeding schemes for existing mouse mutant models for
Peg3. Evaluating the spatial expression of these alternative promoters in the brain may also
provide insight to their functional significance. Sequential deletion of these alternative promoters
using transgenic and knockout mouse models would be informative tools for loss-of-function
studies for Peg3. We speculate that some of these alternative promoters (such as U1) may be
involved in functions such as early developmental regulation and DNA methylation setting of the
Peg3 ICR [18]. Even though the exact mechanism for alternative promoter transcription is not
well explored, this dissertation provides the knowledge and technological advancements
essential for future studies in eukaryotic gene transcriptional regulation, and aids in further
understanding the process of genomic imprinting in the Peg3 imprinted domain.
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